Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2022 Aug 23;18(8):e1010724. doi: 10.1371/journal.ppat.1010724

Human coronaviruses disassemble processing bodies

Mariel Kleer 1,2,3,#, Rory P Mulloy 1,2,3,#, Carolyn-Ann Robinson 1,2,3, Danyel Evseev 1,2,3, Maxwell P Bui-Marinos 1,2,3, Elizabeth L Castle 4, Arinjay Banerjee 5,6,7,8, Samira Mubareka 8,9, Karen Mossman 10,11, Jennifer A Corcoran 1,2,3,*
Editor: Marjolein Kikkert12
PMCID: PMC9439236  PMID: 35998203

Abstract

A dysregulated proinflammatory cytokine response is characteristic of severe coronavirus infections caused by SARS-CoV-2, yet our understanding of the underlying mechanism responsible for this imbalanced immune response remains incomplete. Processing bodies (PBs) are cytoplasmic membraneless ribonucleoprotein granules that control innate immune responses by mediating the constitutive decay or suppression of mRNA transcripts, including many that encode proinflammatory cytokines. PB formation promotes turnover or suppression of cytokine RNAs, whereas PB disassembly corresponds with the increased stability and/or translation of these cytokine RNAs. Many viruses cause PB disassembly, an event that can be viewed as a switch that rapidly relieves cytokine RNA repression and permits the infected cell to respond to viral infection. Prior to this submission, no information was known about how human coronaviruses (CoVs) impacted PBs. Here, we show SARS-CoV-2 and the common cold CoVs, OC43 and 229E, induced PB loss. We screened a SARS-CoV-2 gene library and identified that expression of the viral nucleocapsid (N) protein from SARS-CoV-2 was sufficient to mediate PB disassembly. RNA fluorescent in situ hybridization revealed that transcripts encoding TNF and IL-6 localized to PBs in control cells. PB loss correlated with the increased cytoplasmic localization of these transcripts in SARS-CoV-2 N protein-expressing cells. Ectopic expression of the N proteins from five other human coronaviruses (OC43, MERS, 229E, NL63 and SARS-CoV) did not cause significant PB disassembly, suggesting that this feature is unique to SARS-CoV-2 N protein. These data suggest that SARS-CoV-2-mediated PB disassembly contributes to the dysregulation of proinflammatory cytokine production observed during severe SARS-CoV-2 infection.

Author summary

Processing bodies (PBs) are cytoplasmic RNA and protein granules that regulate gene expression post-transcriptionally because they degrade or suppress cellular mRNA transcripts. PBs are particularly relevant for the regulation of inflammatory cytokine production because many cytokine RNAs contain sequences that direct them to PBs for rapid turnover or suppression. When PBs disassemble, this increases capacity for cytokine translation. Here, we show PB loss is a conserved feature of CoV infection, including SARS-CoV-2, and that expression of the SARS-CoV-2 nucleocapsid (N) protein is sufficient to mediate PB disassembly. N protein expression also alters the distribution and abundance of inflammatory cytokine transcripts that are typically contained within PBs, thereby returning them to the cytoplasmic pool of mRNA available for translation. Together, these data underscore the importance of PB loss to CoV infection and suggest it may contribute to the aberrant inflammatory nature associated with severe CoV infections.

Introduction

Processing bodies (PBs) are membraneless ribonucleoprotein (RNP) granules found in the cytoplasm of all cells [1,2]. PBs control cellular gene expression because they either degrade or sequester RNA transcripts, preventing their translation into protein. PBs contain many enzymes required for mRNA turnover, including those needed for decapping (Dcp2 and co-factors Dcp1a and Edc4/Hedls) and decay of the RNA body (5’-3’ exonuclease Xrn1 and RNA helicase Rck/DDX6) as well as components of the RNA-induced silencing complex [3,4]. Not all coding RNAs are regulated by PBs, but those that are typically encode potent regulatory molecules like growth factors, pro-inflammatory cytokines, and angiogenic factors. One group of protein-coding mRNAs commonly found in PBs bear destabilizing AU-rich elements (AREs) in their 3’-untranslated regions (3’-UTRs) and include most proinflammatory cytokine transcripts [57]. These RNAs shuttle to PBs by virtue of interactions between the AU-rich element and RNA-binding proteins (RBPs) [3,811]. We and others have showed that the presence of PBs correlates with increased turnover/suppression of ARE-mRNAs [7,1215]. Conversely, when PBs are lost, constitutive ARE-mRNA suppression is reversed, and ARE-mRNA transcripts and/or their translation products accumulate. Therefore, PB disassembly can be viewed as a switch that permits cells to rapidly respond and translate ARE-containing proinflammatory cytokine RNA into molecules such as IL-6, IL-8, IL-1β, and TNF [5]. PBs provide an extra layer of post-transcriptional control enabling the cell to fine-tune the production of potent molecules like proinflammatory cytokines.

Although PBs are constitutive, they are also dynamic, changing in size and number in response to different stimuli or stressors. This dynamic disassembly/assembly is possible because PBs behave as biomolecular condensates that form via liquid-liquid phase separation of proteins [1619]. PBs form via sequential multivalent RNA-protein interactions, with a small group of proteins that contain regions of intrinsic disorder serving as the essential scaffold onto which additional proteins or RNA can be recruited as the PB matures [9,16,2024]. Despite the recognition of PBs as dynamic entities, our understanding of the signals that induce PB disassembly remains incomplete. We and others have shown that stressors which activate the p38/MK2 MAP kinase pathway, as well as many virus infections elicit PB disassembly [12,13,15,25,26]. Disassembly can occur by a direct interaction between a viral protein(s) and a PB component that is subsequently re-localized to viral replication and transcription compartments (vRTCs) [2729] or cleaved by viral proteases [3032]. Viruses can also cause PB disassembly indirectly by activating p38/MK2 signaling [12,13,26].

There are numerous reports of viral gene products that trigger PB disassembly, yet corresponding reports of viral gene products that stimulate PB formation are rare, suggesting that PBs possess direct antiviral function and their disassembly may favour viral replication in ways that we do not yet grasp [33,34]. Even though other RNPs, such as stress granules, have emerged as important components of our antiviral defenses that contribute to sensing virus and triggering innate immune responses, evidence to support a direct antiviral role for PBs is less well established [3437]. Such a role has been defined for several PB-localized enzymes that impede viral replication (e.g. APOBEC3G, MOV10); however, in these cases, the mechanism of viral restriction was attributed to the enzymatic activity of the PB protein(s) whereas its localization to PBs was not deemed as significant [28,29,31,3845]. Nonetheless, the disassembly of PBs by diverse viruses strongly suggests they negatively regulate virus replication. The reason viruses disassemble PBs may be to limit their antiviral activity; however, because PBs also control turnover/suppression of many proinflammatory cytokine transcripts, their disruption by viruses contributes to high proinflammatory cytokine levels, alerting immune cells to the infection.

The family Coronaviridae includes seven viruses that infect humans, including the four circulating ‘common cold’ coronaviruses (CoVs), CoV-OC43, CoV-229E, CoV-NL63, and CoV-HKU1 and three highly pathogenic viruses that cause severe disease in humans: MERS-CoV, SARS-CoV, and the recently emerged SARS-CoV-2 [4651]. Severe COVID-19 is characterized by aberrant proinflammatory cytokine production, endothelial cell (EC) dysfunction and multiple organ involvement [5264]. Even with intense study, we do not yet appreciate precisely how SARS-CoV-2 infection causes severe COVID-19 in some patients and mild disease in others, though a mismanaged or delayed IFN response and an overactive cytokine response is thought to underlie severe outcomes [6570]. Despite some contrasting reports [7173], what is clear is that SARS-CoV-2 proteins use a multitude of mechanisms to outcompete cellular antiviral responses [68,7485].

To determine if SARS-CoV-2 and other CoVs interact with PBs to alter the cellular antiviral response, we performed an analysis of PBs after CoV infection. Prior to this submission, no published literature was available on human CoVs and PBs, and only two previous reports mentioned PB dynamics after CoV infection. Murine hepatitis virus (MHV) was reported to increase PBs at early infection times, while transmissible gastroenteritis coronavirus (TGEV) infected cells displayed complete PB loss by 16 hours post infection [86,87]. Observations that SARS-CoV-2 infection induced elevated levels of many PB-regulated cytokines, such as IL-6, IL-10, IL-1β and TNF [53,54,57,69,70] suggested that human CoVs like SARS-CoV-2 may reshape the cellular innate immune response in part by targeting PBs for disassembly. We now present the first evidence to show that three human CoVs, including SARS-CoV-2, trigger PB disassembly during infection. By screening a SARS-CoV-2 gene library, we identified that the nucleocapsid (N) protein was sufficient for PB disassembly. However, this feature is not common to all human coronavirus N proteins, as overexpression of MERS-CoV-N, OC43-N, 229E-N and NL63-N was insufficient to induce PB loss and expression of SARS-CoV-1 N protein displayed an intermediate phenotype. SARS-CoV-2 N protein-mediated PB disassembly also correlated with the redistribution of two PB-regulated cytokine transcripts, TNF and IL-6, from PBs to the cytoplasm and an increase in abundance of TNF RNA. These data suggest that PB disassembly by SARS-CoV-2 N may promote the redistribution of certain cytokine transcripts from PB foci to the cytoplasm. Taken together, these results show that PBs are targeted for disassembly by human CoV infection, and that this phenotype may contribute in part to reshaping cytokine responses to SARS-CoV-2 infection.

Results

Infection with human coronaviruses causes PB loss

Endothelial cells (ECs) have emerged as playing a significant role in severe COVID; as sentinel immune cells they are important sources for many of the cytokines elevated in severe disease and are infected by SARS-CoV-2 in vivo [56,5860,88]. However, others have shown that commercial primary human umbilical vein endothelial cells (HUVECs) require ectopic expression of the viral receptor, ACE2, to be susceptible to SARS-CoV-2 [89]. We recapitulated those findings and showed that after HUVECs were transduced with an ACE2-expressing lentivirus (HUVECACE2), they were permissive to SARS-CoV-2 (Wuhan-like ancestral Toronto isolate; TO-1) [90] (S1A Fig). To use HUVECACE2 for studies on PB dynamics, we confirmed that ACE2 ectopic expression had no effect on PB number in HUVECs (S1B Fig). Confirming this, we infected HUVECACE2 with SARS-CoV-2 (MOI = 3) to determine if PBs were altered. SARS-CoV-2 infected cells were identified by immunostaining for the viral nucleocapsid (N) while PBs were identified by immunostaining for two different PB resident proteins, the RNA helicase DDX6, and the decapping cofactor, Hedls. PBs, measured by staining for both markers, were absent in most SARS-CoV-2 infected HUVECsACE2 by 24 hours post infection (Fig 1A–1D). We quantified the loss of cytoplasmic puncta using a method described previously [91] and showed that by 24 hours post infection, SARS-CoV-2 infected cells displayed a significant reduction in PBs compared to mock-infected controls (Fig 1B and 1D).

Fig 1. Processing bodies are absent in SARS-CoV-2 infected cells.

Fig 1

A-D. HUVECs were transduced with recombinant lentiviruses expressing human ACE2 (HUVECACE2), selected, and infected with SARS-CoV-2 TO-1 isolate at an MOI of 3 or a time-matched mock infection control. At 16 or 24 hours post infection, cells were fixed and immunostained for SARS-CoV-2 N protein (green; Alexa488) and DDX6 (A, white; Alexa555) or Hedls (C, white; Alexa555). Nuclei were stained with Hoechst (blue). Representative images from one of three independent experiments are shown (A, C). PBs were quantified using CellProfiler by measuring DDX6 puncta (B) and Hedls puncta (D) in SARS-CoV-2-infected cells (thresholded by N protein staining) or in mock-infected cells. These data represent three independent biological replicates (n = 3) with >80 cells measured per condition (mock and infected) per replicate. Each mock and infected replicate pair plotted independently (B, D); mean (****, p < 0.0001). E-H. Calu3 cells were infected with SARS-CoV-2 TO-1 isolate (MOI = 3) or time-matched mock-infected control. 24 hours post infection cells were fixed and immunostained for SARS-CoV-2 N (green; Alexa488), DDX6 (E; white; Alexa555) or Hedls (G; white; Alexa555). Nuclei were stained with Hoechst (blue). PBs were quantified using CellProfiler as in B and D (F, H). These data represent three independent biological replicates (n = 3) with >130 cells measured per condition (mock and infected) per replicate. Representative images from one experiment of three are shown (E, G) and each mock and infected replicate pair plotted independently (F, H); mean (****, p < 0.0001). Statistics were performed using a Mann-Whitney rank-sum test. Scale bar = 20 μm.

To confirm that PBs were reduced by SARS-CoV-2 infection of naturally permissive cells derived from respiratory epithelium, we infected Calu-3 cells with SARS-CoV-2. Infected cells were identified by immunostaining for N protein 24 hours post infection and PBs were stained for DDX6 and Hedls. We observed PB loss in most but not all infected cells (Fig 1E–1H). We quantified PB loss and showed that by 24 hours post infection, SARS-CoV-2 infected Calu-3 cells also displayed a significant reduction in PBs compared to mock-infected controls (Fig 1F and 1H). As the SARS-CoV-2 pandemic has progressed, new variants of concern (VOCs) have continued to emerge [92,93]. To determine if VOCs also induced PB disassembly, we infected HUVECACE2 with SARS-CoV-2 VOCs Alpha, Beta, Gamma and Delta (MOI = 2) and compared PB disassembly to an ancestral isolate of SARS-CoV-2 (Wuhan-like Toronto isolate; TO-1) (Fig 2). Infected cells were identified by immunostaining for N protein 24 hours post infection and PBs were identified using Hedls. Significant PB disassembly was observed for all VOCs, although we noted slightly less PB disassembly mediated by TO-1 compared to the experiments in Fig 1, likely due to the decrease in MOI between these two experiments (Fig 2).

Fig 2. Processing bodies are absent in SARS-CoV-2 Alpha, Beta, Gamma, and Delta variant infected cells.

Fig 2

A. HUVECs were transduced with recombinant lentiviruses expressing human ACE2 (HUVECACE2), selected and infected with SARS-CoV-2 TO-1, Alpha, Beta, Gamma, or Delta isolates (MOI = 2), or a mock infection control. 24 hours post infection cells were fixed and immunostained for SARS-CoV-2 N protein (green; Alexa488) and Hedls (white; Alexa555). Nuclei were stained with Hoechst (blue). Representative images from one of two independent experiments are shown. B. PBs were quantified as in Fig 1. These data represent two independent biological replicates (n = 2) with >80 cells measured per condition (mock and infected) per replicate. Each mock and infected replicate pair plotted independently; mean. Statistics were performed using Kruskal-Wallis H test with Dunn’s correction (*, p < 0.0332; ****, p < 0.0001). Scale bar = 20 μM.

To determine if PBs were lost in response to infection with other human coronaviruses, we established infection models for the Betacoronavirus, OC43, and the Alphacoronavirus, 229E. We found HUVECs were permissive to both OC43 and 229E (S2A–S2B Fig). We then performed a time-course experiment wherein OC43-infected HUVECs were fixed at various times post infection and immunostained for the viral N protein and the PB-resident protein DDX6. We observed that PBs were largely absent in OC43 N protein-positive cells but present in mock-infected control cells (Fig 3A and 3B). 229E-infected HUVECs were stained for DDX6 to measure PBs and for dsRNA to denote infected cells due to a lack of commercially available antibodies for 229E. CoV infected cells are known to form an abundance of dsRNA due to viral replication and transcription from a positive-sense RNA genome making this a suitable marker for virally infected cells [94]. In parallel, we confirmed 229E infection by performing RT-qPCR for viral genomic and subgenomic RNA (S2C–S2D Fig). After 229E infection, we also found that PBs were significantly reduced (Fig 3C and 3D). Because of antibody incompatibility, we were unable to co-stain infected cells for the PB protein Hedls and OC43 N protein or dsRNA. In lieu of this, we performed additional OC43 and 229E infections and co-stained infected cells using antibodies for Hedls and DDX6 (S3 Fig). We then performed additional quantification of PB loss using the Hedls marker to label PBs. These data also show robust PB loss in response to infection with OC43 and 229E (S3 Fig).

Fig 3. Processing bodies are absent in OC43 and 229E infected cells.

Fig 3

A-B. HUVECs were infected with OC43 (TCID50 = 2 x 104) or mock-infected. Cells were fixed at 12 or 24 hours post infection and immunostained for DDX6 (PBs; white; Alexa555) and OC43 N protein (green; Alexa488). Nuclei were stained with Hoechst (blue). These data represent three independent biological replicates (n = 3) with >80 cells measured per condition (mock and infected) per replicate. Representative images from one of three experiments are shown. DDX6 puncta in mock or OC43-infected cells were quantified as in Fig 1. Each mock and infected replicate pair plotted independently; mean. C-D. HUVECs were infected with 229E (TCID50 = 2.4 x 103) or mock-infected. Cells were fixed at 6 or 12 hours post infection and immunostained for DDX6 (PBs; white; Alexa555) and dsRNA (proxy for 229E infection; green; Alexa488). Nuclei were stained with Hoechst (blue). These data represent three independent biological replicates (n = 3) with >80 cells measured per condition (mock and infected) per replicate. Representative images from one of three experiments are shown. DDX6 puncta in mock or 229E-infected (dsRNA+) cells were quantified as in Fig 1. Each mock and infected replicate pair plotted independently; mean. Statistics were performed using a Mann-Whitney rank-sum test (****, p < 0.0001). Scale bar = 20 μM.

PBs will disassemble if key scaffolding proteins are lost; these include the RNA helicase DDX6, the translation suppressor 4E-T, the decapping cofactors Hedls/EDC4 and DCP1A, and the scaffolding molecule Lsm14A [95]. To elucidate if CoV-infected cells displayed decreased steady-state levels of PB resident proteins, we immunoblotted infected cell lysates for PB proteins XRN1, DCP1A, or DDX6, and Hedls (Fig 4) and quantified protein levels by densitometry (S4 Fig). SARS-CoV-2 infection of HUVECACE2 cells did not alter steady-state levels of these proteins compared to uninfected cells (Fig 4A). OC43-infected HUVECs displayed comparable levels of XRN1, DCP1A, and Hedls relative to uninfected cells; however, OC43 infection decreased steady-state levels of DDX6 (Fig 4B). 229E-infected HUVECs showed no significant change in PB protein expression after infection compared to controls (Fig 4C).

Fig 4. Coronavirus infection does not alter steady state levels of most processing body proteins.

Fig 4

A. HUVECs were transduced with human ACE2 (HUVECACE2), selected, and infected with SARS-CoV-2 TO-1 isolate (MOI = 3). Cells were lysed at 6 and 12 hours post infection and immunoblotting was performed using XRN1, Hedls, DCP1A, DDX6, SARS-CoV-2 N, and β-actin specific antibodies. One representative experiment of two is shown. B-C. HUVECs were infected with OC43 (B, TCID50 = 2 x 104) or 229E (C, TCID50 = 2.4 x 103). Cells were lysed at 12 and 24 hours post infection (B, OC43) or 6 and 12 hours post infection (C, 229E). Immunoblotting was performed using XRN1, Hedls, DCP1A, DDX6, OC43 N protein (B only), and β-actin specific antibodies. One representative experiment of three is shown.

PBs are important sites for the post-transcriptional control of inflammatory cytokine transcripts containing AU-rich elements, and PB loss correlates with enhanced levels of some of these transcripts [7,1215]. To determine if ARE-mRNAs are elevated, and therefore subject to this type of regulation during CoV infection, we harvested total RNA from SARS-CoV-2-, OC43- or 229E-infected HUVECs and performed RT-qPCR for five ARE-containing cytokine transcripts, IL-6, CXCL8, COX-2, GM-CSF, and IL-1β (Fig 5A–5C). We attempted to quantify TNF RNA as well, but the low copy number (high Ct value) of TNF RNA in mock control samples made quantification by RT-qPCR inaccurate and we were unable to measure the fold-increase of TNF RNA after CoV infection. We observed increased levels of three ARE-containing transcripts, IL-6, CXCL8, and COX-2, compared to uninfected cells, particularly in SARS-CoV-2-infected HUVECACE2 cells (Fig 5A). Taken together, these data indicate that infection with human CoVs including SARS-CoV-2 induces PB loss, and that some PB-regulated cytokine ARE-mRNAs are elevated during CoV infection.

Fig 5. Steady state levels of selected ARE-mRNAs are elevated during coronavirus infection.

Fig 5

A. HUVECs were transduced with recombinant lentiviruses expressing human ACE2 (HUVECACE2), selected, and infected with SARS-CoV-2 TO-1 isolate (MOI = 3). RNA was harvested 24 hours post infection and RT-qPCR was performed using IL-6, CXCL8, COX-2, GM-CSF, IL-1β and HPRT (house-keeping gene) specific primers. Values are represented as fold change relative to mock-infection. n = 3; mean ± SD (*, p < 0.05; **, p< 0.01; ns, nonsignificant). B-C. HUVECs were infected with OC43 (B, TCID50/mL = 3.5 x 104) or 229E (C, TCID50/mL = 1 x 103.24). RNA was harvested 24 and 12 hours post infection for OC43 (B) and 229E (C), respectively, and RT-qPCR was performed as in (A). Values are represented as fold change relative to mock-infection. Statistics were performed using an unpaired Student’s t-test. n≥3; mean ± SD (*, p < 0.05; **, p < 0.01; ns, nonsignificant).

A screen of SARS-CoV-2 genes reveals mediators of PB loss

The genome of SARS-CoV-2 is predicted to contain up to 14 open reading frames (ORFs). The two 5’ proximal ORFs (1a and 1ab) encode two large polyproteins which are processed by viral proteases into 16 non-structural proteins (nsp1-16) essential for viral genome replication and transcription [46]. The 3’ end of the SARS-CoV-2 genome is predicted to code for ORFs that are expressed from 9 subgenomic mRNAs [96]. Among these are the four structural proteins spike (S), envelope (E), membrane (M) and nucleocapsid (N) and up to 9 potential accessory proteins, not all of which have been validated as expressed in infected cells [96]. To test which SARS-CoV-2 gene product(s) was responsible for PB disassembly, we obtained a plasmid library of 27 SARS-CoV-2 genes from the Krogan lab; this library included 14 nsps (excluding nsp3 and nsp16), all structural (S, E, M, N) and candidate accessory genes (ORFs 3a, 3b, 6, 7a, 7b, 8, 9b, 9c, 10) [96]. We individually transfected each plasmid and immunostained for each of the SARS-CoV-2 proteins using antibodies to the Strep-tag II and for PBs using anti-DDX6 (Figs 6A and S5). Relative to control cells, many SARS-CoV-2 ORF transfected cells still displayed DDX6-positive PBs; however, expression of some SARS-CoV-2 genes reduced DDX6-positive puncta, including N and ORF7b (Fig 6A) to a similar or greater extent than our positive control, the KapB protein from Kaposi’s sarcoma-associated herpesvirus, which we have previously shown causes PB disassembly (Fig 6B and 6C) [13,91,97,98]. We quantified the number of DDX6-positive PBs per cell for each transfection as in [91] and found that the average number of PBs per cell was reduced relative to our negative control after transfection of eight SARS-CoV-2 genes: nsp7, ORF7b, N, ORF9b, ORF3b, nsp6, nsp1, and nsp11 (Fig 6D and 6E). This quantification was performed in two different ways. In most cases, transfected cells were identified by co-staining for the Strep-tag II fused to each gene (Figs 6A and S5). In such cases, we quantified DDX6-positive puncta only in those cells that were transfected and not in bystander cells (Fig 6D, thresholded). These data identified three SARS-CoV-2 proteins that may cause PB loss in a cell autonomous manner: nsp7, ORF7b and N (Fig 6D). For the remaining transfections (nsp1, nsp5, nsp6, nsp11, nsp13, nsp14, ORF3b, ORF6, ORF9b, ORF9c) immunostaining for the Strep-tag II was not robust and we were unable to threshold our PB counts (S5 Fig). In these samples, we quantified PBs in all cells of the monolayer (Fig 6E, unthresholded). These data identified five additional SARS-CoV-2 proteins from our screen that may cause PB loss: ORF9b, ORF3b, nsp1, nsp6 and nsp11 (Fig 6E). We verified the expression of all constructs, including low expressors (nsp1, nsp5, nsp6, nsp11, nsp13, nsp14, ORF3b, ORF6, ORF9b and ORF9c) by immunoblotting whole cell lysates harvested from parallel transfections (Fig 6F). We were unable to detect nsp4, ORF9c or ORF10 by immunoblotting; however, we did visualize expression of these proteins by immunostaining (Figs 6F and S5). We eliminated low confidence hits (nsp7, ORF9b) and low expressors (nsp6, nsp11) from further studies and proceeded with validation of the top four hits (ORF7b, N, ORF3b, nsp1).

Fig 6. Identification of SARS-CoV-2 ORFs that mediate processing body loss.

Fig 6

A. HeLa cells expressing GFP-Dcp1a were transfected with an empty vector (EV) or 2X Strep-tagged SARS-CoV-2 ORFs for 48 hours then fixed and immunostained for Strep-tag II (viral ORF; green; Alexa647) or DDX6 (PBs; white; Alexa555). Nuclei were stained with Hoechst (blue). Staining of select ORFs from one of three independent experiments are shown in A. B. As a positive control for PB disassembly, HeLa GFP-Dcp1a cells were transfected with EV or the Kaposi’s sarcoma-associated herpesvirus (KSHV) protein, KapB for 48 hours then fixed and immunostained for KapB (green; Alexa647) or Hedls (PBs; white; Alexa555). Nuclei were stained with Hoechst (blue); Scale bar = 20 μm. C. Hedls puncta were quantified as in Fig 1. These data represent three independent replicates (n = 3). Statistics were performed using an unpaired Student’s t-test; (**, p < 0.01). D-E. DDX6 puncta were quantified using CellProfiler. In D, SARS-CoV-2 ORF-expressing cells were thresholded by Strep-tag II staining intensity. The intensity threshold used was defined as two standard deviations above mean intensity in vector controls. Only DDX6 puncta in cells above this threshold were counted. In E, Strep-tag II staining could not be visualized above this threshold; therefore, DDX6 puncta in all cells were counted (unthresholded). Values are expressed as a fold-change difference normalized to the vector control (hashed line). These data represent three or more independent replicates (n≥3). A one-way ANOVA with a Dunnett’s post-hoc analysis was performed; bars represent SEM (**, p < 0.01). N = nucleocapsid protein, E = envelope protein, M = membrane protein, S = spike protein F. HeLa GFP-Dcp1a cells were transfected as in A. 48 hours post transfection cells were lysed. Samples were resolved by SDS-PAGE on 4–15% gradient gels and immunoblotted with a Strep-tag II antibody.

The nucleocapsid protein of SARS-CoV-2 induces PB disassembly

We tested four top hits from our PB screen in more relevant endothelial cells as these cells can be infected, express inflammatory cytokines, and stain robustly for PBs. HUVECs were transduced with recombinant lentiviruses expressing N, nsp1, ORF3b, and ORF7b or empty vector control lentiviruses. We also included recombinant lentiviruses expressing nsp14 in this experiment because of its exoribonuclease activity and ability to diminish cellular translation and interferon responses [84]. Transduced cells were selected for transgene expression and then fixed and stained for the endogenous PB marker protein DDX6 and for the Strep-tag II on each of SARS-CoV-2 constructs. We observed robust staining of the viral nucleocapsid (N) protein in the transduced cell population (Fig 7A) but were unable to detect expression of nsp1, nsp14, ORF3b or ORF7b by immunostaining (S6A Fig). We quantified PB loss in the selected cells and observed decreased PB numbers in cell populations expressing N, nsp14, ORF3b and ORF7b; however, the most robust PB loss was induced in N-expressing cells, which displayed a significant reduction in PB numbers as well as strong immunostaining (Figs 7B and S6). We were concerned that we could not detect the other four transgenes by immunostaining; therefore, we performed immunoblotting for the Strep-II tag on lysates from each transduced cell population (S6C Fig). Although we detected a strong band of ~50 kDa at the predicted molecular weight for N, we were unable to detect bands for nsp14, ORF3b and ORF7b, while the most prominent band for nsp1 did not migrate at the predicted molecular weight of ~20 kDa (S6 Fig) [99,100]. For these reasons, we decided to focus the remainder of our analysis on the N protein.

Fig 7. Ectopic expression of SARS-CoV-2 N elicits processing body disassembly.

Fig 7

A-B. HUVECs were transduced with recombinant lentiviruses ectopically expressing 2X Strep-tagged SARS-CoV-2 N or empty vector control (EV) and selected with puromycin for 48 hours. Samples were fixed and immunostained for Strep-tag II (N; green) and DDX6 (PBs; white). Nuclei were stained with Hoechst (blue). Representative images from one of three independent experiments are shown (n = 3). Scale bar = 20 μm. DDX6 puncta were quantified per field of view using CellProfiler as in Fig 1. >30 cells were measured per condition (EV and N) per replicate. Bars represent the mean. Mann-Whitney rank-sum test was performed (****, p < 0.0001). C-F. HUVECs were transduced and selected as in A, then treated with 0.25 mM sodium arsenite (NaAsO2) or a vehicle control (Untreated) for 30 minutes, fixed and immunostained for either Hedls (C, white; Alexa555) or DDX6 (D, white; Alexa555) and SARS-CoV-2 N (green; Alexa488). Nuclei were stained with Hoechst (blue). Scale bar = 20 μm. Representative images from one independent experiment of three are shown. These data represent five (C, D) or four (E, F) independent replicates, with >30 cells measured per condition per replicate. Hedls puncta (D) and DDX6 puncta (F) were quantified as in Fig 1. Bars represent the mean. Statistics were performed using a two-way ANOVA with a Tukey’s multiple comparisons test (*, p < 0.0332; ****, p < 0.0001; ns, nonsignificant).

As PBs are dynamic RNP granules that undergo transient disassembly and assembly under basal conditions, we wanted to determine whether N-mediated PB loss was caused by enhanced disassembly of PBs or the prevention of PB de novo assembly. To determine this, we treated N-expressing HUVECs with sodium arsenite, a known inducer of PB assembly [101] and immunostained PBs for two different PB resident proteins, DDX6 and Hedls. Consistent with our previous observation, significant PB loss was observed after N expression in our untreated control when PBs were labeled using an antibody to DDX6 but not using an antibody to Hedls (Fig 7C–7F). The lack of significant disassembly of Hedls-stained PB puncta by N protein could be attributed to one outlier experiment where the control cells lacked sufficient PBs, a biological variability that is observed between different batches of primary cells such as HUVECs. However, after treatment with sodium arsenite, all N protein-expressing cells displayed robust PB formation regardless of the PB protein antibody used (Fig 7C–7F). This means that N protein expression does not prevent PB formation, but instead triggers PB disassembly, which can be reversed after an appropriate stimulus like sodium arsenite. These data showed that N expression is sufficient to cause PB loss, and that the absence of PBs in N-expressing cells is a result of enhanced PB disassembly not a block in PB formation.

We showed that human CoVs OC43 and 229E also cause PB loss during infection (Fig 3); therefore, we were interested to determine if ectopic expression of nucleocapsid proteins from these or other human CoVs were sufficient to mediate PB disassembly. To test this, we transduced HUVECs with recombinant lentiviruses expressing the N protein from SARS-CoV-2 as well as N protein derived from Betacoronaviruses, MERS-CoV and OC43. Expression of MERS-CoV and OC43 N proteins did not lead to significant PB loss compared to SARS-CoV-2 N (Fig 8A and 8B). We also tested two N proteins from human Alphacoronaviruses, 229E and NL63. 229E N protein failed to induce significant PB loss compared to SARS-CoV-2 N, while unexpectedly, it appeared the expression of NL63 N protein increased PB numbers (Fig 8C and 8D). The significance of this increase is not yet clear. We also expressed the N protein from the more closely related Betacoronavirus, SARS-CoV-1, and observed SARS-CoV-1 N protein caused moderate PB loss, yet SARS-CoV-1 N protein-induced PB disassembly was not deemed significant by statistical analysis (Fig 8E and 8F). We collected protein lysates in parallel and performed immunoblotting to detect each CoV N protein (Fig 8G–8I). We noted that CoV N proteins were not expressed equally (S7 Fig), with the important caveat that a direct comparison between individual N protein expression is not accurate as blotting was performed with different antibodies. Nonetheless, we cannot fully discount expression level as the reason for the discrepancy in PB disassembly. This may be especially important for our analysis of SARS-CoV-1 N protein, which showed an intermediate but non-significant PB disassembly phenotype but was expressed at a lower level that SARS-CoV-2 N protein (Fig 8I). Immunoblotting of steady state levels of PB resident proteins after N protein overexpression showed that most PB proteins tested remained unchanged (Figs 8G–8I and S7A). The exception to this was the decapping factor, Hedls/EDC4, which was decreased after expression of SARS-CoV-2 N in one set of experiments but increased after expression of N proteins from MERS and OC43 (Figs 8G–8I and S7A). The significance of this observation is also unclear.

Fig 8. Processing body disassembly is not a common feature of all human coronavirus N proteins.

Fig 8

A-D. HUVECs were transduced with recombinant lentiviruses ectopically expressing N protein from the Betacoronaviruses MERS-CoV and OC43 (A-B) or N protein from Alphacoronaviruses 229E and NL63 (C-D) or N protein from SARS-CoV-1 (E-F). A control lentiviral expressing an empty vector (EV) was used as a negative control and SARS-CoV-2 N protein expressing lentiviruses were used as a positive control in each experiment. Cells were selected, fixed and immunostained for DDX6 (PBs; white; Alexa555) and either authentic N protein or a FLAG tag (green; Alexa488). Nuclei were stained with Hoechst (blue). Scale bar = 20 μm. DDX6 puncta in EV or N-transduced cells were quantified using CellProfiler as in Fig 1. DDX6 puncta were quantified as in Fig 1. Representative images from one independent experiment of three are shown. These data represent three independent biological replicates (n = 3) with >30 cells measured per condition (EV and N) per replicate. Each EV and N replicate pair plotted independently; mean. Statistics were performed using Kruskal-Wallis H test with Dunn’s correction (*, p < 0.0332; **, p < 0.0021; ****, p < 0.0001; ns, nonsignificant). G-I. HUVECs were transduced as above, protein lysate was harvested and immunoblotting was performed using XRN1, Hedls, DCP1A, DDX6, N protein or FLAG, and β-actin specific antibodies. One representative experiment of three is shown.

To understand if PB disassembly correlates with changes to PB-regulated inflammatory cytokine transcripts in our system, we performed immunofluorescence-RNA fluorescent in situ hybridization (IF-FISH) to confirm the localization of inflammatory RNAs to PB foci. RNA FISH was performed for two PB-regulated cytokine transcripts that contain AREs, those encoding IL-6 and TNF, and for the GAPDH RNA, which does not contain AREs and is not expected to localize to PBs [3]. To achieve a better signal-to-noise ratio for detection, we used TNF to induce the transcription of IL-6 and TNF in untreated cells. First, we confirmed that TNF treatment alone did not significantly alter PB dynamics (S8 Fig). We then stained PBs using our antibody to Hedls and co-stained with probes that bound GAPDH, TNF and IL-6 RNA transcripts. We repeatedly observed co-localization of IL-6 and TNF RNA with PBs while in contrast, we observed extremely limited GAPDH co-localization with PBs (Fig 9A). IL-6 and TNF transcripts were also present at much lower levels than GAPDH RNA, consistent with the notion that ARE-containing transcripts are kept low by tight transcriptional control and constitutive decay in PBs [14]. We then performed IF-FISH on SARS-CoV-2 N protein-expressing cells or controls using the same protocol (Figs 9B, 9C, and S9A–S9B). N-expressing cells demonstrated PB disassembly compared to control cells, a phenotype that correlated with the redistribution of the IL-6 and TNF probe signal to the cytoplasm (S9 Fig). We quantified the change in FISH probe signal intensity per cell (Fig 9C). Compared to controls, N protein-expressing cells displayed significantly increased TNF probe signal intensity and a noticeable but non-significant increase in IL-6 probe signal intensity, whereas GAPDH probe signal intensity was not increased (Fig 9C). It is probable that this increase in TNF and IL-6, but not GAPDH, probe signal intensity resulted from the release of these ARE-containing RNAs following N protein-mediated PB disassembly (Figs 9 and S9). These data support our hypothesis that upon PB disassembly, PB-regulated transcripts like TNF are redistributed from PB foci to the cytoplasm where they are available for translation.

Fig 9. ARE-mRNAs colocalize with processing bodies.

Fig 9

A. HUVECs were treated with 0.01 ng/L soluble TNF to increase transcription of ARE-containing cellular mRNAs for 24 hours. Cells were fixed and immunostained for Hedls (green; Alexa488) prior to hybridization with Stellaris probes specific for GAPDH, IL-6 and TNF. Nuclei were stained with DAPI. Cells were imaged using a Zeiss LSM 880 confocal microscope with Airyscan using the 63X objective. At least three Z-stacks were acquired per condition (probe) per replicate and a maximal intensity projection (MIP) image is presented. One representative experiment of three is shown. Scale bar = 5 μm. B-C. HUVECs were transduced with recombinant lentiviruses ectopically expressing SARS-CoV-2 N or an EV control. Cells were selected, fixed and immunostained for Hedls (Alexa488, not shown here) prior to hybridization with Stellaris probes specific for GAPDH, IL-6 and TNF (Quasar 670). Nuclei were stained with DAPI. Only probe-specific staining is displayed for simplicity. Scale bar = 20 μm. Representative images from one of three independent experiments are shown. Total signal intensity per cell was quantified using CellProfiler and is represented as fold-change relative to the intensity in the EV control. Statistics were performed using an unpaired Student’s t-test. n = 3; mean ± SD (*, p < 0.05; ns, nonsignificant).

We then asked if N protein from SARS-CoV-2 or other human CoVs would increase ARE RNA-containing transcripts by RT-qPCR. We analyzed IL-6 and TNF transcript level, as well as two other ARE-containing RNAs, encoding CXCL8 and COX-2 which were elevated after infection with SARS-CoV-2 and OC43 (Fig 5). In uninduced ECs, the transcription of these mRNAs is minimal; for example, TNF mRNA could not be readily detected by RT-qPCR without transcriptional activation. Therefore, we treated control and N-expressing HUVECs with TNF to activate cytokine transcription which enabled us to assess if N protein expression enhanced cytokine mRNA level post-transcriptionally. In the absence of TNF, no change of mRNA abundance was observed for any of the CoV N proteins tested (Fig 10A–10C, 0 hour no treatment). Ectopic expression of SARS-CoV-2 N enhanced transcript levels of IL-6, CXCL8, and TNF 24 hours after transcription was induced; however, this enhancement was not deemed significant by statistical analysis (Fig 10A–10C). In contrast, we did not observe any increase in transcript levels after expression of N protein from MERS-CoV, OC43, 229E, or NL63 (Fig 10A–10C), consistent with earlier observations that their expression does not induce PB loss.

Fig 10. Ectopic expression of SARS-CoV-2 N and analysis of selected ARE-mRNAs.

Fig 10

A-C. HUVECs were transduced with recombinant lentiviruses ectopically expressing Alpha- and Betacoronavirus N proteins or empty vector (EV) control, selected, and treated with 0.01 ng/L soluble TNF to increase transcription of ARE-containing cellular mRNAs. Total RNA was harvested at 0, 8, 12, and 24 hours post TNF treatment and RT-qPCR was performed using IL-6 (A), CXCL8 (B), TNF (C) and HPRT (house-keeping gene) specific primers. Values are represented as fold-change relative to EV-transduced cells for each time point. These data represent three independent experiments (n = 3); mean ± SD.

Taken together, we present the finding that three human CoVs induce PB loss and that for SARS-CoV-2, the N protein is responsible for this loss. Moreover, we tested five other human CoV N proteins and found that of these, only SARS-CoV-2 N was sufficient to induce significant PB disassembly and concomitantly redistributed and enhanced levels of PB-localized cytokine mRNAs.

Discussion

In this manuscript, we present the first evidence to show that human CoVs, including SARS-CoV-2, induce PB loss after infection. PBs are fundamental sites of post-transcriptional control of gene expression and are particularly relevant to the regulation of cytokine production. Our major findings are as follows: i) Three human CoVs, SARS-CoV-2, OC43, and 229E induced PB loss. ii) The SARS-CoV-2 nucleocapsid (N) protein was sufficient to cause PB loss. iii) N protein expression correlated with the elevated abundance and re-distribution of the PB-regulated cytokine transcript encoding TNF. Taken together, these data point to PB loss as a feature of SARS-CoV-2 infection. Moreover, because virus-induced PB disassembly elevates some PB-regulated cytokine transcripts, this phenotype may contribute to the dysregulation of proinflammatory molecules observed in severe SARS-CoV-2 infection.

We screened 27 SARS-CoV-2 gene products by transfection in HeLa cells [96] and initially identified eight candidate genes that reduced PB numbers (Fig 6). Validation of a subset of these in HUVECs revealed that the most robust and consistent mediator of PB loss was the SARS-CoV-2 N protein (Fig 7). Since the submission of this work, one additional study showed that SARS-CoV-2 N protein caused PB loss, further strengthening our findings [102].

The N protein is the most abundantly produced protein during CoV replication [103]. The SARS-CoV-2 N protein is 419 amino acids long and has two globular and three intrinsically disordered protein domains, including a central disordered serine-arginine (SR-rich) linker region [103105]. The N protein is a multifunctional RNA-binding protein (RBP) essential for viral replication; it coats the viral genome and promotes viral particle assembly [46,105108]. Several recent reports have shown that N protein undergoes liquid-liquid phase separation with RNA, an event which may be regulated by phosphorylation of multiple serine residues in the SR-region and is an important feature of viral assembly [108113]. The N protein is also an important modulator of antiviral responses [85,114,115]. A recent study showed that low doses of N protein suppressed the production of IFN and some PB-regulated inflammatory cytokines, while high doses of N protein promoted their production [85]. These observations are consistent with our phenotype of PB disassembly, which correlates with later infection times, high expression of N protein and immunofluorescent staining throughout the cytoplasm (Figs 1 and 7).

We subsequently screened five other coronavirus N proteins from OC43, MERS, 229E, NL63, and SARS-CoV-1 and discovered that the phenotype of N-mediated PB disassembly was not conserved among N proteins but was unique to SARS-CoV-2 N, and perhaps SARS-CoV-1 N protein which appeared to disassemble PBs in two of three independent experiments (Fig 8). Despite conservation of some structural motifs, the N protein contains several regions of intrinsic disorder, a feature that may explain why human CoV N proteins display low sequence conservation at the amino acid level (~25–50%) and have been reported to exhibit different properties [116]. In contrast, SARS-CoV-1 and SARS-CoV-2 N proteins have ~94% amino acid identity [117], making it difficult to reconcile our observation that PB disassembly induced by SARS-CoV-2 N protein was significant, while PB disassembly induced by SARS-CoV-1 N protein was not (Fig 8). One difference that we observed by immunoblotting was the presence of a lower molecular weight band recognized by our anti-N antibody for SARS-CoV-2. We did not observe any smaller N protein products after OC43 infection, transduction with OC43 N protein or transduction with C-terminally Flag-tagged N proteins from 229E, NL63, MERS-CoV or SARS-CoV-1 (Figs 3 and 8). Steady state levels of the lower molecular weight N product increased over the course of SARS-CoV-2 infection, consistent with the timing of PB disassembly. Other groups have noted that the SARS-CoV-2 variant of concern (VOC), Alpha, produces an additional subgenomic mRNA from which a truncated version of N, termed N*, can be produced [68,118,119]. Translation of the N* ORF is predicted to start at an internal in-frame methionine residue (Met210) within the N protein [118,119]. Alignment of the SARS-CoV-2 N protein sequence against other N proteins revealed that of the human CoVs, only SARS-CoV-1 and SARS-CoV-2 N retained a methionine at position 210 (229E: NC_002645.1, HKU1: NC_006577.2, MERS: NC_019843.3, NL63: NC_005831.2, OC43: NC_006213.1, SARS-1: NC_004718.3, SARS-2: NC_045512.2). However, a lower molecular weight N protein product was not observed on our immunoblots for SARS-CoV-1 N protein, leading us to speculate that the downstream Met residue may not be used for translation initiation in this case. Viruses capitalize on downstream methionine residues to translate truncated protein products with subcellular localization or functions that differ from their full-length counterparts as a clever way to increase coding capacity [120,121]. Our ongoing investigation of the precise nature of the SARS-CoV-2 N protein truncation product we observe during infection and overexpression may reveal that it has a specific role in PB disassembly.

The PB protein MOV10, and other components of RNA processing machinery, were revealed as potential interactors with the N protein [102,122]; however, we did not observe colocalization of N protein with PBs after immunofluorescent staining of SARS-CoV-2 infected cells or N-expressing cells. Based on our data, we consider two possible mechanisms of N protein mediated PB disassembly. First, N protein may mediate PB disassembly by phase separation with a PB protein(s). This is similar to what has already been shown for N-mediated disruption of cytoplasmic stress granules, important cytoplasmic biomolecular condensates that correlate with cellular translational shutdown [35]. N protein localizes to stress granules and binds the essential protein, G3BP1, preventing its interaction with other stress granule proteins and blocking stress granule formation [123125]. Although the precise domain required for this effect has been debated, more than one report suggests that the N-terminal intrinsically disordered region is required for stress granule disruption [124,126]. Second, a possible reason for PB loss may be the indiscriminate binding of RNA by N protein. N protein could be acting as sponge for RNA, pulling it out of cytoplasm, thereby reducing the RNA-protein interactions required for phase separation of PBs [24,123]. We are currently engaged in site-directed and truncation mutagenesis studies to determine the precise region(s) of SARS-CoV-2- N that is essential for PB disassembly.

Prior to this report, little was known about CoVs and PBs, and the information that was published was contradictory. Infection with murine hepatitis virus (MHV) was reported to increase PBs, whereas transmissible gastroenteritis coronavirus (TGEV) decreased PBs [86,87]. Since the initiation of our study, one additional publication used ectopic expression of one of the SARS-CoV-2 CoV proteases, nsp5, to test if it was capable of PB disassembly. Consistent with the results of our screen (Fig 6), nsp5 did not mediate PB loss [32]. In this manuscript, we now confirm that SARS-CoV-2, OC43, and 229E induce PB disassembly (Figs 13) [34]. We also observed that different human CoVs cause PB loss using different viral gene products; SARS-CoV-2 utilizes N protein, however OC43 and 229E do not, a diversity which further underscores that convergence on PB disassembly by viruses likely benefits viral replication. Because PBs are composed of numerous cellular molecules with established (e.g. APOBEC, MOV10) or potential (decapping enzymes and exonucleases that could degrade viral RNA) antiviral activities, it is possible that viruses may target PBs for disassembly to negate their antiviral activity [28,29,31,3945,127]. A recent screen for cellular proteins that bind SARS-CoV-2 viral RNA captured two PB proteins (Lsm14a and MOV10), which suggests CoV RNA may be shuttled to PBs [128]. That said, our evidence does not yet discern if the proposed antiviral role of PB-localized enzymes is promoted by phase separation of molecules into PBs or not; if so, we would predict that the antiviral function of these molecules is lost when PB granules decondense. Emerging evidence suggests that activity of the decapping enzymatic complex is increased by phase separation and decreased in solution [9,24,129]. Thus, we speculate that PBs are direct-acting antiviral granules that can restrict virus infection when present as visible condensates; for this reason, they are targeted for disassembly by most viruses.

One possibility is that PBs are antiviral because their proteins help the cell respond to signals that activate innate immune pathways [28,30,130,131]. In support of this, TRAF6 was shown to control Dcp1a localization to PBs using ubiquitylation, suggesting that antiviral signaling is more complex than previously appreciated and integrates transcriptional responses with cytokine mRNA suppression in PBs [130,132]. Moreover, the PB protein Lsm14A has been shown to bind to viral RNA/DNA after infection-induced PB disassembly to promote IRF3 activation and IFN-β production [131]. Although it remains unclear if the higher order condensation of many proteins into PBs is required for their proposed antiviral activity, what is clear is that the outcome of PB disassembly is a reversal of the constitutive decay or translational suppression of cytokine mRNA that would normally occur there [7,1215,133]. Our data support a role for PBs as sensors of virus infection that release cytokine transcripts from repression when they disassemble. Using IF-FISH, we observed that RNAs encoding IL-6 and TNF, two molecules elevated in severe SARS-CoV-2 disease, localized to PBs. Upon SARS-CoV-2 N-induced PB disassembly, these transcripts re-localized from PB foci to the cytoplasm, a redistribution that was also accompanied by an increase in FISH probe signal intensity signifying increased RNA abundance for the TNF transcript (Fig 9). Although we did not see a statistically significant increase in IL-6 and TNF RNA in SARS-CoV-2 N-expressing cells using a population-based assay like RT-qPCR (Fig 10), our single-cell analysis by IF-FISH suggests that the biological relevance of our observation derives from the combined increase of transcript abundance plus the redistribution of cytokine transcripts from PB foci to the cytoplasm. We speculate that viral infection causes PB loss and this event is viewed as a danger signal by the cell: it relieves cytokine mRNA suppression and re-localizes these transcripts, returning them to the cytoplasmic pool of RNA to permit translation of proinflammatory cytokines that then act as a call for reinforcements. In this way, PB disassembly is connected to the innate immune response and is one of many signals that notify the immune system that a cell is infected. In situations where interferon responses are delayed or defective, as is emerging for SARS-CoV-2 and severe COVID-19 [6567], PB disassembly may occur to alert the immune system of an infection, and may be a contributing factor to pathogenic cytokine responses.

In summary, our work adds to a growing body of literature which describes that many viruses target PBs for disassembly, supporting the idea that PBs restrict viral infection. We showed that the N protein of SARS-CoV-2 is sufficient for PB disassembly, and this phenotype correlated with elevated levels of PB-localized cytokine transcripts which are elevated during SARS-CoV-2 infection [53]. Not only does this work describe a previously uncharacterized cellular event that occurs during CoV infection, but we have identified a novel mechanism which may contribute to the dysregulated cytokine response exhibited by severe SARS-CoV-2 infection.

Materials and methods

Cell culture and drug treatments

All cells were maintained in humidified 37°C incubators with 5% CO2 and 20% O2. Vero E6 (ATCC), HEK293T cells (ATCC), HeLa Tet-Off cells (Clontech) and HeLa Flp-In TREx GFP-Dcp1a cells (a generous gift from Dr. Anne-Claude Gingras) were cultured in DMEM (Thermo Fisher) supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine (Thermo Fisher) and 10% heat-inactivated fetal bovine serum (FBS, Thermo Fisher). Calu3 (ATCC) and MRC-5 cells (ATCC, a generous gift from Dr. David Proud) were cultured in EMEM (ATCC) supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine and 10% FBS (Thermo Fisher). HUVECs (Lonza) were cultured in endothelial cell growth medium (EGM-2) (Lonza). HUVECs were seeded onto tissue culture plates or glass coverslips coated with 0.1% (w/v) porcine gelatin (Sigma) in 1x PBS. For sodium arsenite treatment, HUVECs were treated with 0.25 mM sodium arsenite (Sigma) or a vehicle control for 30 min.

Plasmids and cloning

pLenti-IRES-Puro SARS-CoV-2 plasmids were a generous gift from the Krogan Lab [96]. pLJM1-OC43-N was cloned from pGBW-m4134906, a gift from Ginkgo Bioworks & Benjie Chen (Table 1; Addgene plasmid #151960; http://n2t.net/addgene:151960; RRID:Addgene_151960) using BamHI and EcoRI restriction sites (NEB). pLJM1-NL63-N-FLAG was cloned from pGBW-m4134910, a gift from Ginkgo Bioworks & Benjie Chen (Addgene plasmid #151939; http://n2t.net/addgene:151939; RRID:Addgene151939) using BamHI and EcoRI. pLJM1-229E-N-FLAG was cloned from pGBW-m4134902, a gift from Ginkgo Bioworks & Benjie Chen (Addgene plasmid #151912; http://n2t.net/addgene:151912; RRID:Addgene151912) using BamHI and EcoRI. Codon-optimized pLJM1-MERS-CoV-N-FLAG was cloned from SinoBiological (cat #VG40068-CF) using BamHI and EcoRI. Codon-optimized pLJM1-SARS-CoV-N-FLAG was cloned SinoBiological (cat# VG40588-NF) using BamHI and EcoRI. The Kaposi’s sarcoma-associated herpesvirus Kaposin B (KapB, KS lung isolate) clone in pLJM1 was previously described [91].

Table 1. Plasmids.

Plasmid Use Source Mammalian Selection
pLJM1-Puro Empty Vector Control [91] [136] Puromycin
pLJM1-BSD Empty Vector Control [136] Blasticidin
pLJM1-ACE2 Overexpression Blasticidin
pMD2.G Lentivirus Generation Addgene #12259 N/A
psPAX2 Lentivirus Generation Addgene #12260 N/A
pLJM1-OC43-N Overexpression Addgene #151960 Puromycin
pLJM1-229E-N-FLAG Overexpression Addgene #151912 Puromycin
pLJM1-NL63-N-FLAG Overexpression Addgene #151939 Puromycin
pLJM1-MERS-CoV-N-FLAG Overexpression SinoBiological #VG40068-CF Puromycin
pLJM1-SARS-CoV-1-N-FLAG Overexpression SinoBiological # VG40588-NF Puromycin
pLenti-SARS-CoV-2-IRES-strep Overexpression library N Krogan (UCSF) [96] Puromycin

Transient transfections

Transient transfections were performed using Fugene (Promega) according to manufacturer’s guidelines. Briefly, HeLa Flp-In TREx GFP-Dcp1a cells were seeded in 12-well plates at 150,000 cells/well in antibiotic-free DMEM containing FBS. Cells were transfected with 1 μg of DNA and 3 μL of Fugene for 48 hours before processing.

Production and use of recombinant lentiviruses

All recombinant lentiviruses were generated using a second-generation system. HEK293T cells were transfected with psPAX2, MD2-G, and the lentiviral transfer plasmid containing a gene of interest using polyethylenimine (PEI, Polysciences). 6 hours after transfection, serum-free media was replaced with DMEM containing serum but no antibiotics. Viral supernatants were harvested 48 hours post transfection and frozen at -80°C until use. For transduction, lentiviruses were thawed at 37°C and added to target cells in complete media containing 5 μg/mL polybrene (Sigma). After 24 hours, the media was replaced with selection media containing 1 μg/mL puromycin or 5 μg/mL blasticidin (ThermoFisher) and cells were selected for 48 h before proceeding with experiments.

Immunofluorescence

Cells were seeded onto 18mm round, #1.5 coverslips (Electron Microscopy Sciences) for immunofluorescence experiments. Following treatment, cells were fixed for 10 or 30 (if infected with SARS-CoV-2) minutes in 4% (v/v) paraformaldehyde (Electron Microscopy Sciences). Samples were permeabilized with 0.1% (v/v) Triton X-100 (Sigma-Aldrich) for 10 minutes at room temperature and blocked in 1% human AB serum (Sigma-Aldrich) in 1X PBS 1 hour at room temperature. Primary and secondary antibodies (Table 2) were diluted in 1% human AB serum and used at the concentrations in Table 2. In all figures except Figs 9 and S9, PBs were labeled with an Alexa 555-conjugated secondary antibody to minimize bleed through into the PB channel that was being quantified. Nuclei were stained with 1 μg/ml Hoechst (Invitrogen). Samples were mounted with Prolong Gold AntiFade mounting media (ThermoFisher). Images were captured using a Zeiss AxioObserver Z1 microscope with the 40X oil-emersion objective unless otherwise stated in the respective figure caption. To account for variability in staining, all experiments contained internal controls (negative control; mock or EV). During image acquisition, exposure time was kept consistent within an independent experiment.

Table 2. Antibodies.

Antibody Species Vendor/Catalog # Application Dilution
Strep-Tag II Mouse Sigma (71590-M) Immunofluorescence
Immunoblot
1:1000
1:1000
DDX6 Rabbit Bethyl (A300-461) Immunofluorescence
Immunoblot
1:1000
1:1000
Hedls Mouse Santa Cruz (sc-8418) Immunofluorescence
Immunoblot
1:1000
1:1000
Dcp1a Rabbit Novus (H00055802-M06) Immunoblot 1:1000
Xrn1 Mouse Abcam (ab231197) Immunoblot 1:1000
Coronavirus OC43 Nucleocapsid Mouse Millipore (MAB-9012) Immunofluorescence
Immunoblot
1:500
1:1000
SARS-CoV-2 Nucleocapsid Rabbit Novus (NBP3-05730) Immunofluorescence 1:1000
SARS-CoV-2 Nucleocapsid Mouse Novus (NBP3-05706) Immunofluorescence
Immunoblot
1:1000
1:1000
dsRNA clone J2 Mouse Millipore (MABE-1134) Immunofluorescence 1:100
FLAG Mouse CST (8146) Immunofluorescence
Immunoblot
1:1000
1:1000
Actin HRP-conjugated Rabbit CST (5215) Immunoblot 1:10,000
Alexa Fluor 555 anti-mouse IgG Donkey Invitrogen (A31570) Immunofluorescence 1:1000
Alexa Fluor 555 anti-rabbit IgG Donkey Invitrogen (A31572) Immunofluorescence 1:1000
Alexa Fluor 488 anti-mouse IgG Goat Invitrogen (A11029) Immunofluorescence 1:1000
Alexa Fluor 488 anti-rabbit IgG Chicken Invitrogen (A21441) Immunofluorescence 1:1000
Alexa Fluor 647 anti-mouse IgG Chicken Invitrogen (A21463 Immunofluorescence 1:1000

Immunofluorescence (IF) RNA Fluorescent In Situ Hybridization (FISH)

IF-FISH was performed according to manufacturer’s protocol (Stellaris IF-FISH protocol). Briefly, cells were fixed in 4% formaldehyde (Sigma-Aldrich) for 10 minutes then permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) in PBS for 10 minutes. Primary Hedls antibody was diluted in PBS and incubated for 1 hour at room temp, following which an Alexa 488-conjugated secondary antibody was likewise diluted in PBS and incubated for 1 hour at room temp. In some experiments, N protein was also stained using primary anti-N protein rabbit antibody and an Alexa 555-conjugated secondary antibody. After IF, cells were fixed in 4% formaldehyde for 10 minutes, washed with 1X PBS, and incubated in Wash Buffer A (LGC Biosearch) for 5 minutes. Stellaris probes; GAPDH Quasar 670 (LGC Biosearch, VSMF 2151–5, probe sequences proprietary), IL-6 Quasar 670 (LGC Biosearch, SMF 1065–5, custom order, probe sequences detailed in Table 3) and TNF Quasar-670 (LGC Biosearch, SMF 1065–5, custom order, probe sequences detailed in Table 3) were diluted in Hybridization Buffer (LGC Biocearch) to a concentration of 125 nM and cells were incubated for hybridization at 37°C overnight. The following day, cells were washed sequentially with Wash Buffer A for 30 minutes, Wash Buffer A containing 5 ng/mL DAPI (Invitrogen) for 30 minutes, and Wash Buffer B (LGC Biosearch) for 5 minutes. Samples were mounted with Prolong Gold AntiFade mounting media (ThermoFisher). Samples were imaged on a Zeiss LSM 880 laser scanning confocal microscope using the 63X 1.4 NA Oil Plan-Apo objective and the following lasers (excitation wavelengths): Diode (405nm), Argon (488nm), and Helium/Neon (561nm and 633nm) with emission filter ranges of 410-513nm, 489-605nm, 570-659nm and 638-755nm, respectively. At least three z-stacks were acquired per condition, maximal intensity projections (MIPs) of 18 slices with dimensions of 1912 x 1912 pixels are presented.

Table 3. Probes for RNA Fluorescent in situ hybridization.

Target: IL-6 TNF
gatagagcttctctttcgtt cgtctgagggttgttttcag
agaaggagttcatagctggg gggtcagtatgtgagaggaa
agaaggcaactggaccgaag atcatgctttcagtgctcat
cggctacatctttggaatct caaagtgcagcaggcagaag
aagaggtgagtggctgtctg cggggttcgagaagatgatc
atttgtttgtcaattcgttc cttgagggtttgctacaaca
agatgccgtcgaggatgtac accagctggttatctctcag
tcacacatgttactcttgtt ctgatggtgtgggtgaggag
tctttggaaggttcaggttg tctggtaggagacggcgatg
aagcatccatctttttcagc ctcttgatggcagagaggag
ctcctcattgaatccagatt gatagatgggctcataccag
tgatgattttcaccaggcaa attgatctcagcgctgagtc
ctggaggtactctaggtata caaagtcgagatagtcgggc
tcctcactactctcaaatct aaagtagacctgcccagact
tactcatctgcacagctctg ctcctcacagggcaatgatc
caggaactggatcaggactt ttgggaaggttggatgttcg
gggtggttattgcatctaga gtctgaaggagggggtaata
tgagatgagttgtcatgtcc gtggtcttgttgcttaaagt
aactccttaaagctgcgcag ctgaatcccaggtttcgaag
catgctacatttgccgaaga ttgaattcttagtggttgcc
acaggtttctgaccagaaga agggatcaaagctgtaggcc
aacataagttctgtgcccag tggtctccagattccagatg
ctcatacttttagttctcca cattctggccagaaccaaag
ttcaaactgcatagccactt taggtgaggtcttctcaagt
ccaagaaatgatctggctct aaggtccacttgtgtcaatt
atttgaggtaagcctacact acatctggagagaggaaggc
cgtgtctcaaggaagtctgg
ctacatgggaacagcctatt
caaaagaaggcacagaggcc
ttggtcaccaaatcagcatt
agaggctcagcaatgagtga
gggcgattacagacacaact
ctttatttctcgccactgaa

Immunoblotting

Cells were lysed in 2X Laemmli buffer and stored at -20°C until use. The DC Protein Assay (Bio-Rad) was used to quantify protein concentration as per the manufacturer’s instructions. 10–15 μg of protein lysate was resolved by SDS-PAGE on TGX Stain-Free acrylamide gels (BioRad). Total protein images were acquired from the PVDF membranes after transfer on the ChemiDoc Touch Imaging system (BioRad). Membranes were blocked in 5% BSA in TBS-T (Tris-buffered saline 0.1% Tween-20). Primary and secondary antibodies were diluted in 2.5% BSA, dilutions can be found in Table 2. Membranes were visualized using Clarity Western ECL substrate and the ChemiDoc Touch Imaging system (BioRad). Densitometry was conducted using ImageJ, area under the curve for each band was calculated, normalized to the respective beta actin loading control band, and presented as fold change.

Quantitative PCR

RNA was collected using the RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s instructions and stored at -80°C until further use. RNA concentration was determined using NanoDrop OneC (ThermoFisher) and 500 ng of RNA was reverse transcribed using qScript XLT cDNA SuperMix (QuantaBio) using a combination of random hexamer and oligo dT primers, according to the manufacturer’s instructions. Depending on starting concentration, cDNA was diluted between 1:10 and 1:20 for qPCR experiments and SsoFast EvaGreen Mastermix (Biorad) was used to amplify cDNA. The ΔΔquantitation cycle (Cq) method was used to determine the fold change in expression of target transcripts using HPRT as a housekeeping control gene. Variance in the mock or empty vector samples was calculated by dividing the ΔCt value of a single replicate by the average ΔCt value of all replicates for that specific gene and condition. qPCR primer sequences can be found in Table 4.

Table 4. qPCR primers.

Target Direction Sequence 5’➔3’
HPRT Forward CTTTCCTTGGTCAGGCAGTATAA
HPRT Reverse AGTCTGGCTTATATCCAACACTTC
18S Forward TTCGAACGTCTGCCCTATCAA
18S Reverse GATGTGGTAGCCGTTTCTCAGG
IL6 Forward GAAGCTCTATCTCGCCTCCA
IL6 Reverse TTTTCTGCCAGTGCCTCTTT
CXCL8 Forward AAATCTGGCAACCCTAGTCTG
CXCL8 Reverse GTGAGGTAAGATGGTGGCTAAT
IL-1β Forward CTCTCACCTCTCCTACTCACTT
IL-1β Reverse TCAGAATGTGGGAGCGAATG
TNF Forward TCGAACCCCGAGTGACAA
TNF Reverse AGCTGCCCCTCAGCTTG
GM-CSF Forward AAATGTTTGACCTCCAGGAGCC
GM-CSF Reverse ATCTGGGTTGCACAGGAAGTT
COX-2 Forward CCCTTGGGTGTCAAAGGTAA
COX-2 Reverse GCCCTCGCTTATGATCTGTC
229E 5’ Leader Forward AGTTGCTTTTTAGACTTTGTGTCT
229E gRNA (ORF1a) Reverse CAAGTGTCACACGGTTGCAG
229E sgRNA (N) Reverse CCACGTTGTGGTTCAGATGC

Virus stocks and virus propagation

Experiments with SARS-CoV-2 and variants were conducted in a containment level-3 (CL3) facility, and all standard operating procedures were approved by the CL3 Oversight Committee and Biosafety Office at the University of Calgary. Stocks of SARS-CoV-2 Toronto-01 isolate (SARS-CoV-2/SB3-TYAGNC) [90], Alpha, Beta, Gamma and Delta were propagated in Vero E6 cells. To produce viral stocks, Vero E6 cells were infected at an MOI of 0.01 for 1 hour in serum-free DMEM at 37°C. Following adsorption, DMEM supplemented with 2% heat inactivated FBS and 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine was added to the infected wells. 24–60 hours post infection, the supernatant was harvested and centrifuged at 500 x g for 5 minutes to remove cellular debris. Virus stocks were aliquoted and stored at -80°C for single use. SARS-CoV-2 titres were enumerated using plaque assays on Vero E6 cells as previously described [134] using equal parts 2.4% w/v semi-solid colloidal cellulose overlay (Sigma; prepared in ddH2O) and 2X DMEM (Wisent) with 1% heat inactivated FBS and 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine.

Experiments with hCoV-OC43 (ATCC VR-1558) and hCoV-229E (ATCC VR-740) were conducted in under containment level-2 conditions. hCoV-OC43 and hCoV-229E were propagated in Vero E6 and MRC-5 cells, respectively. Cells were infected at an MOI of 0.01 for 1 hour in serum-free media at 33°C. Following adsorption, the viral inoculum was removed and replaced with fresh media supplemented with 2% heat inactivated FBS and 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine. After 5–6 days post infection, the supernatant was harvested and cellular debris was cleared by centrifugation. Virus stocks were aliquoted and stored at -80°C. hCoV-OC43 and hCoV-229E titres were enumerated using Reed and Muench tissue-culture infectious dose 50% (TCID50) in Vero E6 or MRC-5 cells, respectively.

Virus infection

For experimental infections, cells were seeded into wells to achieve ~80% confluency at the time of infection. The growth media was removed and replaced with 100 μL of viral inoculum diluted in serum-free DMEM to reach the desired MOI and incubated at 37°C for 1 hour, rocking the plate every 10 minutes. Following incubation, the virus inoculum was removed and replaced with 1 mL of complete growth media.

Processing body and FISH probe intensity quantification

Processing bodies were quantified using an unbiased image analysis pipeline generated in the freeware CellProfiler4.0.6 (cellprofiler.org) [135] as in [91]. First, nuclear staining was used to identify individual cells applying a binary threshold and executing primary object detection between 65 and 200 pixels for HUVECs/HUVECACE2 and 40 and 200 pixels for Calu3s. For each identified object (nuclei), the peripheral boundary of each cell was defined using the “Propagation” function. Propagation distance was customized depending on cell type to account for variance in cell size (150 pixel radius from the nuclei for HUVECs/HUVECACE2, 60 pixel radius from nuclei for Calu3s). Using a subtractive function to remove the nuclei from the total cell area, the cytoplasm of each cell was defined. The cytoplasm area mask was then applied to the matched image stained for PB proteins (DDX6 or Hedls) to count only cytoplasmic puncta. Importantly, multiple nuclei in close proximity (e.g., within the propagation distance) would be divided into mutually exclusive cells, such that a single PB could not be counted more than once. Cells were stratified into ‘positive cells’ (staining for viral proteins or dsRNA) or ‘bystander cells’. In control treatments (e.g., mock infected or EV) PBs in all cells were quantified. In treatment cells only ‘positive cells’ were quantified except in Figs 6E (unthresholded) and S9 Fig (no N protein stain). Background staining was reduced using the “Enhance Speckles” function. Due to increased background created by the IF-FISH staining procedure, cells with high background staining in the PB channel were excluded from quantification for S9 Fig. Only DDX6 or Hedls-positive puncta with a defined size (3–13 pixels) and intensity range were quantified using “global thresholding with robust background adjustments” function. All thresholds were consistent within each replicate that used identical staining parameters. PBs were quantified per cell, either control (EV or mock) or treatment (infected or viral protein expressing). For each experiment, an equal number of control and treatment cells were analyzed. For Fig 5, puncta counts were exported and RStudio was used for data analysis and PB numbers in treatment cells were represented relative to control cells for ease of data interpretation, rather than raw PBs per cell. For Fig 9, nuclei and cells were defined according to HUVEC boundaries as specified above. Background of probe specific staining was reduced using a global thresholding strategy with a minimum cross entropy method of execution. The MeasureImageIntensity function was then used to identify the total intensity per image which was divided by the number of cells identified within that image for a final readout of total intensity/cell. A minimum of 40 cells were quantified per condition.

Statistics

All statistical analyses were performed using GraphPad Prism 9.0. ‘Per cell’ processing body counts were plotted such that each independent biological replicate (including paired control and treatment) could be visualized on a single graph. Given that per cell processing body counts are naturally skewed and thus non-parametric, we elected to use rank-sum statistical methods (Mann-Whitney U test and Kruskal Wallis test) when appropriate, as indicated in the corresponding figure caption. In the case of Fig 7, a two-way ANOVA with a Tukey’s post-hoc analysis was used to determine significance to (1) avoid the false discovery rate associated with multiple t-tests and (2) because sodium arsenite-induced processing bodies appeared to be parametrically distributed. Parametric distribution was assumed on all normalized data (Figs 5, 6, 9, 10, S4 and S7) and therefore we elected to use unpaired t-tests or one-way ANOVAs with Dunnett’s post-hoc analysis, as indicated in the corresponding figure caption.

Supporting information

S1 Fig. HUVEC-ACE2 cells are permissive to SARS-CoV-2.

A. HUVECs were transduced with recombinant lentiviruses expressing human ACE2 (HUVECACE2), selected, and infected with SARS-CoV-2 (TO-1 isolate; MOI = 3). 6 and 24 hours post-infection, virus-containing supernatant was harvested and titrated by TCID50 assay in VeroE6 cells. These data represent two independent experiments (n = 2); mean ± SD. B-C. HUVECs were transduced with ACE2 as in A. Cells were fixed and immunostained for DDX6 (B) or Hedls (C) and quantified per field of view using CellProfiler. These data represent two independent experiments (n = 2) with >100 cells measured per condition. Each EV and ACE2 replicate pair plotted independently; mean. Statistics were performed using a Mann-Whitney rank-sum test (ns, nonsignificant).

(TIFF)

S2 Fig. HUVECs are permissive to OC43 and 229E infection.

A-B. HUVECs were infected with OC43 (TCID50 = 2 x 104) or 229E (TCID50 = 2.4 x 103). 6-, 12-, or 24 hours post infection, virus-containing supernatant was harvested and titrated using TCID50 assay in VeroE6 (A) or MRC5 (B) cells, respectively. These data represent two independent experiments (n = 2); mean ± SD. C. HUVECs were infected with 229E as in B or mock infected. Total RNA was harvested 12 hours post infection and RT-qPCR was performed using primers specific to 229E genomic RNA (gRNA) or subgenomic RNA8 (sgRNA8), or HPRT (cellular house-keeping gene). Cycle-threshold (Ct) values for each primer pair were plotted. These data represent three independent experiments (n = 3); mean ± SD. Ct values greater than 35 were not deemed biologically relevant and therefore are scored as N/A. D. PCR products from C were resolved using agarose gel electrophoresis. gRNA fragment migrated at the expected size of 285 bp. sgRNA fragment migrated at its expected ~80 bp. Representative images from one of two independent experiments are shown.

(TIFF)

S3 Fig. Hedls puncta are absent in OC43 and 229E infected cells.

A. HUVECs were infected with OC43 (TCID50 = 2 x 104) or mock-infected. 12 or 24 hours post infection cells were fixed and immunostained for DDX6 (green; Alexa488) and Hedls (white; Alexa555). Nuclei were stained with Hoechst (blue). Representative images from one of three independent experiments shown. B. Hedls puncta in OC43-infected or mock-infected cells were quantified per field of view using CellProfiler. C. HUVECs were infected with 229E (TCID50 = 2.4 x 103) or mock-infected. 6 or 12 hours post infection cells were fixed and immunostained for DDX6 (green) and Hedls (white). Nuclei were stained with Hoechst (blue). Representative images from one of three independent experiments shown. D. Hedls puncta in 229E-infected or mock-infected cells were quantified as in B. These data represent three independent experiments (n = 3) with ≥100 cells measured per condition per replicate. Each mock and infected replicate pair plotted independently; mean. Statistics were performed using a Mann-Whitney rank-sum test (****, p < 0.0001). Scale bar = 20 μm.

(TIFF)

S4 Fig. Processing body protein densitometry after human coronavirus infection.

A. HUVECs were transduced with human ACE2 (HUVECACE2), selected, and infected with SARS-CoV-2 TO-1 isolate (MOI = 3). Cells were lysed at 6 and 12 hours post infection and immunoblotting was performed using XRN1, Hedls, DCP1A, DDX6, SARS-CoV-2 N, and β-actin specific antibodies. The results of the second independent experiment of two is shown. B-C. HUVECs were infected with OC43 (TCID50 = 2 x 104) or 229E (TCID50 = 2.4 x 103) or mock-infected. Cells were lysed at 12 and 24 hours post infection (B, OC43) or 6 and 12 hours post infection (C, 229E). Immunoblotting was performed using DDX6, Hedls, XRN1, DCP1A, and beta actin specific antibodies. Protein densitometry was determined in ImageJ normalized to beta actin and expressed as a fold-change relative to the 12 hours post infection (B; OC43) or 6 hours post infection (C; 229E) mock-infected control. These data represent three independent biological replicates (n = 3). A one-way ANOVA with a Dunnett’s post-hoc analysis was performed; mean; bars represent SD (*, p < 0.05).

(TIFF)

S5 Fig. Ectopic expression of SARS-CoV-2 ORFs.

HeLa cells expressing GFP-Dcp1a were transfected with an empty vector (EV) control or 2X Strep-tagged SARS-CoV-2 ORFs for 48 hours then fixed and immunostained for Strep-tag II (viral ORF; green; Alexa647) or DDX6 (PBs; white; Alexa555). Nuclei were stained with Hoechst (blue). A. SARS-CoV-2 ORFs that could be detected by Strep-tag II staining (thresholded ORFs). B. SARS-CoV-2 ORFs that could not be detected by Strep-tag II staining (unthresholded ORFs). Representative images from one of three or more independent experiments shown. Scale is the same for all images. M = membrane protein, S = spike protein.

(TIFF)

S6 Fig. Validation of processing body loss induced by selected SARS-CoV-2 ORFs in HUVECs.

A. HUVECs were transduced with recombinant lentiviruses expressing 2X Strep-tagged SARS-CoV-2 nsp1, nsp14, ORF3b, and ORF7b constructs or control lentiviruses (EV) and selected with puromycin for 48 hours. Cells were fixed and immunostained for Strep-tag II (ORFs; green; Alexa488) and DDX6 (PBs; white; Alexa555). Nuclei were stained with Hoechst (blue). Representative images from one of three independent experiments shown. Scale bar = 20 μm. B. DDX6 puncta were quantified per field of view using CellProfiler. These data represent three independent experiments (n = 3) with >18 cells measured per condition per replicate. Each EV and ORF-expressing replicate pair plotted independently; mean. Statistics were performed using Kruskal-Wallis H test with Dunn’s correction (**, p < 0.0021; ****, p < 0.0001; ns, nonsignificant). C. HUVECs were transduced as in A. Cells were lysed and immunoblotting was performed using the Strep-Tag II antibody on a 4–15% gradient gel.

(TIFF)

S7 Fig. Processing body protein densitometry after CoV N protein overexpression.

A-C. HUVECs were transduced with recombinant lentiviruses ectopically expressing N protein from the Betacoronaviruses MERS-CoV and OC43 (A), N protein from Alphacoronaviruses 229E and NL63 (B) or SARS-CoV-1 N (C). A control lentiviral expressing an empty vector (EV) was used as a negative control and SARS-CoV-2 N protein expressing lentiviruses were used as a positive control in each experiment. Cells were selected and lysed and immunoblotting was performed using XRN1, Hedls, DCP1A, DDX6, N protein or FLAG, and beta actin specific antibodies. Protein densitometry was determined in ImageJ normalized to beta actin and expressed as a fold-change relative to the EV control. These data represent three independent biological replicates (n = 3). A one-way ANOVA with a Dunnett’s post-hoc analysis was performed; mean; bars represent SD (*, p < 0.05).

(TIFF)

S8 Fig. TNF treatment does not alter processing body number.

HUVECs were treated with 0.01 ng/L soluble TNF for either 6 or 12 hours following which, cells were fixed and immunostained for Hedls. Nuclei were stained with Hoechst. Hedls puncta were quantified per field of view using CellProfiler. These data represent two independent experiments (n = 2) with >90 cells measured per condition per replicate. Each mock and infected replicate pair plotted independently; mean.

(TIFF)

S9 Fig. Processing body loss correlates with elevated TNF RNA after ectopic expression of SARS-CoV-2 N protein.

A-B. Cells were treated and immunostained as in Fig 9B and Hedls puncta (white; Alexa488) were quantified per field of view using CellProfiler. Scale bar = 20 μm. These data represent three independent experiments (n = 3) with >75 cells measured per condition per replicate; mean. Statistics were performed using a Mann-Whitney rank-sum test (****, p < 0.0001). C-D. HUVECs were transduced with recombinant lentiviruses ectopically expressing SARS-CoV-2 N or an EV control. Cells were selected, fixed and immunostained for either Hedls (green; Alexa488) and SARS-CoV-2 N (red; Alexa555) prior to hybridization with Stellaris probes specific for GAPDH and TNF (grey; Quasar 670). Nuclei were stained with DAPI. Cells were imaged using a Zeiss LSM 880 laser scanning confocal microscope and the 63X objective. Representative images from two independent experiments are shown. Each channel is shown separately in black and white, including an inverted image of the RNA FISH channel, prior to merged images. Scale bar = 5 μm.

(TIFF)

Acknowledgments

We sincerely thank the members of the Corcoran lab, Dr. Craig McCormick and Dr. Eric Pringle for helpful discussions about this work. We would like to thank Dr. Nevan Krogan (UCSF) for the SARS-CoV-2 gene library, Dr. David Proud (University of Calgary) for MRC-5 cells, and Dr. Lorne Tyrrell, Dr. Michael Joyce and Holly Bandi (University of Alberta) for isolates of SARS-CoV-2 variants Alpha, Beta, Gamma and Delta. We would like to thank Dr. Anne Vaahtokari of the Charbonneau Microscopy Facility for microscopy support and Dr. Devender Kumar for CL3 facility support.

Data Availability

All relevant data are within the manuscript and its supporting files.

Funding Statement

MK was supported by a Cumming School of Medicine graduate training award, a Canadian Institutes for Health Research (CIHR) CGS-M scholarship, and a CIHR doctoral award and RPM was supported by a Snyder Institute Beverley Phillips Doctoral training award and a CIHR doctoral award. This study was supported by operating funds awarded to JAC from the Canadian Institutes for Health Research: a COVID rapid response operating grant (#177704) and an operating grant (#175622) to the Coronavirus Variants Rapid Response Network (CoVaRR-Net), of which JAC is a member. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Eulalio A, Behm-Ansmant I, Schweizer D, Izaurralde E. P-body formation is a consequence, not the cause, of RNA-mediated gene silencing. Mol Cell Biol. 2007;27: 3970–3981. doi: 10.1128/MCB.00128-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Eulalio A, Rehwinkel J, Stricker M, Huntzinger E, Yang S-F, Doerks T, et al. Target-specific requirements for enhancers of decapping in miRNA-mediated gene silencing. Genes Dev. Cold Spring Harbor Lab; 2007;21: 2558–2570. doi: 10.1101/gad.443107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Hubstenberger A, Courel M, Bénard M, Souquere S, Ernoult-Lange M, Chouaib R, et al. P-Body Purification Reveals the Condensation of Repressed mRNA Regulons. Mol Cell. Elsevier Inc; 2017;68: 144–157.e5. doi: 10.1016/j.molcel.2017.09.003 [DOI] [PubMed] [Google Scholar]
  • 4.Youn J-Y, Dunham WH, Hong SJ, Knight JDR, Bashkurov M, Chen GI, et al. High-Density Proximity Mapping Reveals the Subcellular Organization of mRNA-Associated Granules and Bodies. Mol Cell. Elsevier Inc; 2018;69: 517–532.e11. doi: 10.1016/j.molcel.2017.12.020 [DOI] [PubMed] [Google Scholar]
  • 5.Bakheet T, Hitti E, Khabar KSA. ARED-Plus: an updated and expanded database of AU-rich element-containing mRNAs and pre-mRNAs. Nucleic Acids Research. 2018;46: D218–D220. doi: 10.1093/nar/gkx975 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hitti E, Bakheet T, Al-Souhibani N, Moghrabi W, Al-Yahya S, Al-Ghamdi M, et al. Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins. Cancer Res. 2016;76: 4068–4080. doi: 10.1158/0008-5472.CAN-15-3110 [DOI] [PubMed] [Google Scholar]
  • 7.Blanco FF, Sanduja S, Deane NG, Blackshear PJ, Dixon DA. Transforming growth factor β regulates P-body formation through induction of the mRNA decay factor tristetraprolin. Mol Cell Biol. 2014;34: 180–195. doi: 10.1128/MCB.01020-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Brengues M, Teixeira D, Parker R. Movement of eukaryotic mRNAs between polysomes and cytoplasmic processing bodies. Science. American Association for the Advancement of Science; 2005;310: 486–489. doi: 10.1126/science.1115791 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Riggs CL, Kedersha N, Ivanov P, Anderson P. Mammalian stress granules and P bodies at a glance. J Cell Sci. 2020;133: jcs242487. doi: 10.1242/jcs.242487 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Khong A, Parker R. mRNP architecture in translating and stress conditions reveals an ordered pathway of mRNP compaction. J Cell Biol. 2018;217: 4124–4140. doi: 10.1083/jcb.201806183 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Matheny T, Rao BS, Parker R. Transcriptome-Wide Comparison of Stress Granules and P-Bodies Reveals that Translation Plays a Major Role in RNA Partitioning. Mol Cell Biol. 2019;39: 612. doi: 10.1128/MCB.00313-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Corcoran JA, Khaperskyy DA, Johnston BP, King CA, Cyr DP, Olsthoorn AV, et al. Kaposi’s sarcoma-associated herpesvirus G-protein-coupled receptor prevents AU-rich-element-mediated mRNA decay. J Virol. 2012;86: 8859–8871. doi: 10.1128/JVI.00597-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Corcoran JA, Johnston BP, McCormick C. Viral Activation of MK2-hsp27-p115RhoGEF-RhoA Signaling Axis Causes Cytoskeletal Rearrangements, P-body Disruption and ARE-mRNA Stabilization. Robertson ES, editor. PLoS Pathogens. Public Library of Science; 2015;11: e1004597. doi: 10.1371/journal.ppat.1004597 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Franks TM, Lykke-Andersen J. TTP and BRF proteins nucleate processing body formation to silence mRNAs with AU-rich elements. Genes Dev. 2007;21: 719–735. doi: 10.1101/gad.1494707 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Vindry C, Marnef A, Broomhead H, Twyffels L, Ozgur S, Stoecklin G, et al. Dual RNA Processing Roles of Pat1b via Cytoplasmic Lsm1-7 and Nuclear Lsm2-8 Complexes. CellReports. 2017;20: 1187–1200. doi: 10.1016/j.celrep.2017.06.091 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Vandelli A, Cid Samper F, Torrent Burgas M, Sanchez de Groot N, Tartaglia GG. The Interplay Between Disordered Regions in RNAs and Proteins Modulates Interactions Within Stress Granules and Processing Bodies. J Mol Biol. 2021;: 167159. doi: 10.1016/j.jmb.2021.167159 [DOI] [PubMed] [Google Scholar]
  • 17.Nosella ML, Forman-Kay JD. Phosphorylation-dependent regulation of messenger RNA transcription, processing and translation within biomolecular condensates. Curr Opin Cell Biol. 2021;69: 30–40. doi: 10.1016/j.ceb.2020.12.007 [DOI] [PubMed] [Google Scholar]
  • 18.Jalihal AP, Pitchiaya S, Xiao L, Bawa P, Jiang X, Bedi K, et al. Multivalent Proteins Rapidly and Reversibly Phase-Separate upon Osmotic Cell Volume Change. Mol Cell. 2020;79: 978–990.e5. doi: 10.1016/j.molcel.2020.08.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Mitrea DM, Chandra B, Ferrolino MC, Gibbs EB, Tolbert M, White MR, et al. Methods for Physical Characterization of Phase-Separated Bodies and Membrane-less Organelles. J Mol Biol. 2018;430: 4773–4805. doi: 10.1016/j.jmb.2018.07.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Banani SF, Rice AM, Peeples WB, Lin Y, Jain S, Parker R, et al. Compositional Control of Phase-Separated Cellular Bodies. Cell. 2016;166: 651–663. doi: 10.1016/j.cell.2016.06.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Guillén-Boixet J, Kopach A, Holehouse AS, Wittmann S, Jahnel M, Schlüßler R, et al. RNA-Induced Conformational Switching and Clustering of G3BP Drive Stress Granule Assembly by Condensation. Cell. 2020;181: 346–361.e17. doi: 10.1016/j.cell.2020.03.049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Van Treeck B, Parker R. Emerging Roles for Intermolecular RNA-RNA Interactions in RNP Assemblies. Cell. 2018;174: 791–802. doi: 10.1016/j.cell.2018.07.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Cougot N, Cavalier A, Thomas D, Gillet R. The dual organization of P-bodies revealed by immunoelectron microscopy and electron tomography. J Mol Biol. 2012;420: 17–28. doi: 10.1016/j.jmb.2012.03.027 [DOI] [PubMed] [Google Scholar]
  • 24.Corbet GA, Parker R. RNP Granule Formation: Lessons from P-Bodies and Stress Granules. Cold Spring Harb Symp Quant Biol. 2019;84: 203–215. doi: 10.1101/sqb.2019.84.040329 [DOI] [PubMed] [Google Scholar]
  • 25.Standart N, Weil D. P-Bodies: Cytosolic Droplets for Coordinated mRNA Storage. Trends Genet. 2018;34: 612–626. doi: 10.1016/j.tig.2018.05.005 [DOI] [PubMed] [Google Scholar]
  • 26.Docena G, Rovedatti L, Kruidenier L, Fanning A, Leakey NAB, Knowles CH, et al. Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease. Clin Exp Immunol. John Wiley & Sons, Ltd; 2010;162: 108–115. doi: 10.1111/j.1365-2249.2010.04203.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Jangra RK, Yi M, Lemon SM. DDX6 (Rck/p54) is required for efficient hepatitis C virus replication but not for internal ribosome entry site-directed translation. J Virol. 2010;84: 6810–6824. doi: 10.1128/JVI.00397-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ng CS, Kasumba DM, Fujita T, Luo H. Spatio-temporal characterization of the antiviral activity of the XRN1-DCP1/2 aggregation against cytoplasmic RNA viruses to prevent cell death. Cell Death & Differentiation. Nature Publishing Group; 2020;36: 932–20. doi: 10.1038/s41418-020-0509-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ostareck DH, Naarmann-de Vries IS, Ostareck-Lederer A. DDX6 and its orthologs as modulators of cellular and viral RNA expression. Wiley Interdiscip Rev RNA. 2014;5: 659–678. doi: 10.1002/wrna.1237 [DOI] [PubMed] [Google Scholar]
  • 30.Dougherty JD, Tsai W-C, Lloyd RE. Multiple Poliovirus Proteins Repress Cytoplasmic RNA Granules. Viruses. Multidisciplinary Digital Publishing Institute; 2015;7: 6127–6140. doi: 10.3390/v7122922 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Dougherty JD, White JP, Lloyd RE. Poliovirus-mediated disruption of cytoplasmic processing bodies. J Virol. 2011;85: 64–75. doi: 10.1128/JVI.01657-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Fan S, Xu Z, Liu P, Qin Y, Chen M. Enterovirus 71 2A Protease Inhibits P-Body Formation To Promote Viral RNA Synthesis. J Virol. 2021;95: e0092221. doi: 10.1128/JVI.00922-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kanakamani S, Suresh PS, Venkatesh T. Regulation of processing bodies: From viruses to cancer epigenetic machinery. Cell Biol Int. John Wiley & Sons, Ltd; 2021;45: 708–719. doi: 10.1002/cbin.11527 [DOI] [PubMed] [Google Scholar]
  • 34.Gaete-Argel A, Márquez CL, Barriga GP, Soto-Rifo R, Valiente-Echeverría F. Strategies for Success. Viral Infections and Membraneless Organelles. Front Cell Infect Microbiol. 2019;9: 336. doi: 10.3389/fcimb.2019.00336 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.McCormick C, Khaperskyy DA. Translation inhibition and stress granules in the antiviral immune response. Nature Reviews Immunology. Nature Publishing Group; 2017;17: 647–660. doi: 10.1038/nri.2017.63 [DOI] [PubMed] [Google Scholar]
  • 36.Tsai W-C, Lloyd RE. Cytoplasmic RNA Granules and Viral Infection. Annu Rev Virol. Annual Reviews; 2014;1: 147–170. doi: 10.1146/annurev-virology-031413-085505 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Onomoto K, Jogi M, Yoo J-S, Narita R, Morimoto S, Takemura A, et al. Critical role of an antiviral stress granule containing RIG-I and PKR in viral detection and innate immunity. Kanai A, editor. PLoS ONE. Public Library of Science; 2012;7: e43031. doi: 10.1371/journal.pone.0043031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Abernathy E, Gilbertson S, Alla R, Glaunsinger B. Viral Nucleases Induce an mRNA Degradation-Transcription Feedback Loop in Mammalian Cells. Cell Host and Microbe. 2015;18: 243–253. doi: 10.1016/j.chom.2015.06.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Núñez RD, Budt M, Saenger S, Paki K, Arnold U, Sadewasser A, et al. The RNA Helicase DDX6 Associates with RIG-I to Augment Induction of Antiviral Signaling. Int J Mol Sci. Multidisciplinary Digital Publishing Institute; 2018;19: 1877. doi: 10.3390/ijms19071877 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Balinsky CA, Schmeisser H, Wells AI, Ganesan S, Jin T, Singh K, et al. IRAV (FLJ11286), an Interferon-Stimulated Gene with Antiviral Activity against Dengue Virus, Interacts with MOV10. Diamond MS, editor. J Virol. 2017;91: 504. doi: 10.1128/JVI.01606-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Wang H, Chang L, Wang X, Su A, Feng C, Fu Y, et al. MOV10 interacts with Enterovirus 71 genomic 5’UTR and modulates viral replication. Biochem Biophys Res Commun. 2016;479: 571–577. doi: 10.1016/j.bbrc.2016.09.112 [DOI] [PubMed] [Google Scholar]
  • 42.Cuevas RA, Ghosh A, Wallerath C, Hornung V, Coyne CB, Sarkar SN. MOV10 Provides Antiviral Activity against RNA Viruses by Enhancing RIG-I-MAVS-Independent IFN Induction. J Immunol. 2016;196: 3877–3886. doi: 10.4049/jimmunol.1501359 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Burdick R, Smith JL, Chaipan C, Friew Y, Chen J, Venkatachari NJ, et al. P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages. J Virol. 2010;84: 10241–10253. doi: 10.1128/JVI.00585-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Burgess HM, Mohr I. Cellular 5“-3” mRNA exonuclease Xrn1 controls double-stranded RNA accumulation and anti-viral responses. Cell Host and Microbe. 2015;17: 332–344. doi: 10.1016/j.chom.2015.02.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Lumb JH, Li Q, Popov LM, Ding S, Keith MT, Merrill BD, et al. DDX6 Represses Aberrant Activation of Interferon- Stimulated Genes. CellReports. ElsevierCompany; 2017;20: 819–831. doi: 10.1016/j.celrep.2017.06.085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. Nature Publishing Group; 2020;5: 536–16. doi: 10.1038/s41579-020-00468-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Springer US; 2019;: 1–12. doi: 10.1038/s41579-018-0118-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Banerjee A, Doxey AC, Tremblay BJ-M, Mansfield MJ, Subudhi S, Hirota JA, et al. Predicting the recombination potential of severe acute respiratory syndrome coronavirus 2 and Middle East respiratory syndrome coronavirus. J Gen Virol. Microbiology Society; 2020;101: 1251–1260. doi: 10.1099/jgv.0.001491 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Banerjee A, Doxey AC, Mossman K, Irving AT. Unraveling the Zoonotic Origin and Transmission of SARS-CoV-2. Trends Ecol Evol. 2021;36: 180–184. doi: 10.1016/j.tree.2020.12.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Zhou H, Ji J, Chen X, Bi Y, Li J, Wang Q, et al. Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses. Cell. 2021;184: 4380–4391.e14. doi: 10.1016/j.cell.2021.06.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. American Association for the Advancement of Science; 2005;310: 676–679. doi: 10.1126/science.1118391 [DOI] [PubMed] [Google Scholar]
  • 52.Fielding CA, Jones GW, McLoughlin RM, McLeod L, Hammond VJ, Uceda J, et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity. 2014;40: 40–50. doi: 10.1016/j.immuni.2013.10.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Blanco-Melo D, tenover BR. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;: 1–46. doi: 10.1016/j.cell.2020.04.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Pedersen SF, Ho Y-C. SARS-CoV-2: a storm is raging. Journal of Clinical Investigation. 2020;130: 2202–2205. doi: 10.1172/JCI137647 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. Massachusetts Medical Society; 2020;382: 1177–1179. doi: 10.1056/NEJMc2001737 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 3rd ed. 2020;41: 3038–3044. doi: 10.1093/eurheartj/ehaa623 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. American Society for Clinical Investigation; 2020;130: 2620–2629. doi: 10.1172/JCI137244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. BioMed Central; 2020;24: 353–8. doi: 10.1186/s13054-020-03062-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Lowenstein CJ, Solomon SD. Severe COVID-19 is a Microvascular Disease. Circulation. Lippincott Williams & Wilkins Hagerstown, MD; 2020;191: 148. doi: 10.1161/CIRCULATIONAHA.120.050354 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. The Lancet. Elsevier Ltd; 2020;395: 1417–1418. doi: 10.1016/S0140-6736(20)30937-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Amraei R, Rahimi N. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. Cells. Multidisciplinary Digital Publishing Institute; 2020;9: 1652. doi: 10.3390/cells9071652 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Teuwen L-A, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nature Reviews Immunology. Nature Publishing Group; 2020;20: 389–391. doi: 10.1038/s41577-020-0343-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. Nature Publishing Group; 2021;18: 194–209. doi: 10.1038/s41569-020-00469-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Suvorava T, Kaesemeyer W. Targeting the Vascular Endothelium in the Treatment of COVID-19. J Cardiovasc Pharmacol. 2021;77: 1–3. doi: 10.1097/FJC.0000000000000932 [DOI] [PubMed] [Google Scholar]
  • 65.Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;129: eabd4585. doi: 10.1126/science.abd4585 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;: eabd4570. doi: 10.1126/science.abd4570 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Park A, Iwasaki A. Type I and Type III Interferons—Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host and Microbe. 2020;27: 870–878. doi: 10.1016/j.chom.2020.05.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Thorne LG, Bouhaddou M, Reuschl A-K, Zuliani-Alvarez L, Polacco B, Pelin A, et al. Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant. PlosPath. Cold Spring Harbor Laboratory; 2021;: 2021.06.06.446826. doi: 10.1101/2021.06.06.446826 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Sposito B, Broggi A, Pandolfi L, Crotta S, Clementi N, Ferrarese R, et al. The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell. 2021;184: 4953–4968.e16. doi: 10.1016/j.cell.2021.08.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Ziegler CGK, Miao VN, Owings AH, Navia AW, Tang Y, Bromley JD, et al. Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. Cell. 2021;184: 4713–4733.e22. doi: 10.1016/j.cell.2021.07.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, et al. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell Host and Microbe. 2020;27: 883–890.e2. doi: 10.1016/j.chom.2020.04.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369: 718–724. doi: 10.1126/science.abc6027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Banerjee A, El-Sayes N, Budylowski P, Jacob RA, Richard D, Maan H, et al. Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. iScience. 2021;24: 102477. doi: 10.1016/j.isci.2021.102477 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Yuen C-K, Lam J-Y, Wong W-M, Mak L-F, Wang X, Chu H, et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerging Microbes & Infections. Taylor & Francis; 2020;9: 1418–1428. doi: 10.1080/22221751.2020.1780953 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Miorin L, Kehrer T, Sanchez-Aparicio MT, Zhang K, Cohen P, Patel RS, et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad Sci USA. 2020;5: 202016650–11. doi: 10.1073/pnas.2016650117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Banerjee AK, Blanco MR, Bruce EA, Honson DD, Chen LM, Chow A, et al. SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. Cell. Elsevier Inc; 2020;: 1–66. doi: 10.1016/j.cell.2020.10.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Konno Y, Kimura I, Uriu K, Fukushi M, Irie T, Koyanagi Y, et al. SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant. CellReports. 2020;32: 108185. doi: 10.1016/j.celrep.2020.108185 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Yin X, Riva L, Pu Y, Martin-Sancho L, Kanamune J, Yamamoto Y, et al. MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. CellReports. 2021;34: 108628. doi: 10.1016/j.celrep.2020.108628 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nature Communications. Nature Publishing Group; 2020;11: 3810–12. doi: 10.1038/s41467-020-17665-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Beyer DK, Forero A. Mechanisms of Antiviral Immune Evasion of SARS-CoV-2. J Mol Biol. 2021;: 167265. doi: 10.1016/j.jmb.2021.167265 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Xia H, Cao Z, Xie X, Zhang X, Chen JY-C, Wang H, et al. Evasion of Type I Interferon by SARS-CoV-2. CellReports. 2020;33: 108234. doi: 10.1016/j.celrep.2020.108234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Suryawanshi RK, Koganti R, Agelidis A, Patil CD, Shukla D. Dysregulation of Cell Signaling by SARS-CoV-2. Trends in Microbiology. 2021;29: 224–237. doi: 10.1016/j.tim.2020.12.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Wickenhagen A, Sugrue E, Lytras S, Kuchi S, Noerenberg M, Turnbull ML, et al. A prenylated dsRNA sensor protects against severe COVID-19. Science. American Association for the Advancement of Science; 2021;: eabj3624. doi: 10.1126/science.abj3624 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Hsu JC-C, Laurent-Rolle M, Pawlak JB, Wilen CB, Cresswell P. Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. Proc Natl Acad Sci USA. National Academy of Sciences; 2021;118. doi: 10.1073/pnas.2101161118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Zhao Y, Sui L, Wu P, Wang W, Wang Z, Yu Y, et al. A dual-role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response. Signal Transduct Target Ther. Nature Publishing Group; 2021;6: 331–14. doi: 10.1038/s41392-021-00742-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Sola I, Galán C, Mateos-Gómez PA, Palacio L, Zuñiga S, Cruz JL, et al. The polypyrimidine tract-binding protein affects coronavirus RNA accumulation levels and relocalizes viral RNAs to novel cytoplasmic domains different from replication-transcription sites. J Virol. 3rd ed. 2011;85: 5136–5149. doi: 10.1128/JVI.00195-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Raaben M, Groot Koerkamp MJA, Rottier PJM, de Haan CAM. Mouse hepatitis coronavirus replication induces host translational shutoff and mRNA decay, with concomitant formation of stress granules and processing bodies. Cellular Microbiology. 2007;9: 2218–2229. doi: 10.1111/j.1462-5822.2007.00951.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Ackermann M, Mentzer SJ, Kolb M, Jonigk D. Inflammation and Intussusceptive Angiogenesis in COVID-19: everything in and out of Flow. Eur Respir J. 2020;383: 2003147. doi: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Nascimento Conde J, Schutt WR, Gorbunova EE, Mackow ER. Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses. Patton JT, editor. mBio. American Society for Microbiology; 2020;11. doi: 10.1128/mBio.03185-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Banerjee A, Nasir JA, Budylowski P, Yip L, Aftanas P, Christie N, et al. Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2. Emerging Infect Dis. 2020;26: 2054–2063. doi: 10.3201/eid2609.201495 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Castle EL, Robinson C-A, Douglas P, Rinker KD, Corcoran JA. Viral manipulation of a mechanoresponsive signaling axis disassembles processing bodies. Mol Cell Biol. 2021;: MCB0039921. doi: 10.1128/MCB.00399-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Singh J, Pandit P, McArthur AG, Banerjee A, Mossman K. Evolutionary trajectory of SARS-CoV-2 and emerging variants. Virology Journal. BioMed Central; 2021;18: 166–21. doi: 10.1186/s12985-021-01633-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. Nature Publishing Group; 2021;19: 409–424. doi: 10.1038/s41579-021-00573-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Sola I, Almazán F, Zuñiga S, Enjuanes L. Continuous and Discontinuous RNA Synthesis in Coronaviruses. Annu Rev Virol. Annual Reviews; 2015;2: 265–288. doi: 10.1146/annurev-virology-100114-055218 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Ayache J, Bénard M, Ernoult-Lange M, Minshall N, Standart N, Kress M, et al. P-body assembly requires DDX6 repression complexes rather than decay or Ataxin2/2L complexes. Matera AG, editor. Mol Biol Cell. The American Society for Cell Biology; 2015;26: 2579–2595. doi: 10.1091/mbc.E15-03-0136 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. Nature Publishing Group; 2020;583: 459–468. doi: 10.1038/s41586-020-2286-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Kleer M, MacNeil G, Adam N, Pringle ES, Corcoran JA. A panel of KSHV mutants in the polycistronic kaposin locus for precise analysis of individual protein products. J Virol. American Society for Microbiology 1752 N St., N.W., Washington, DC; 2021;: JVI0156021. doi: 10.1128/JVI.01560-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Robinson C-A, Singh GK, Kleer M, Castle EL, Boudreau BQ, Corcoran JA. Kaposi’s sarcoma-associated herpesvirus (KSHV) utilizes the NDP52/CALCOCO2 selective autophagy receptor to disassemble processing bodies. In revision for PLoS Pathogens. 2022;: biorxiv doi: 10.1101/2021.02.07.430164 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Min Y-Q, Mo Q, Wang J, Deng F, Wang H, Ning Y-J. SARS-CoV-2 nsp1: Bioinformatics, Potential Structural and Functional Features, and Implications for Drug/Vaccine Designs. Front Microbiol. Frontiers; 2020;11: 587317. doi: 10.3389/fmicb.2020.587317 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Zeng W, Liu G, Ma H, Zhao D, Yang Y, Liu M, et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun. 2020;527: 618–623. doi: 10.1016/j.bbrc.2020.04.136 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Kedersha N, Stoecklin G, Ayodele M, Yacono P, Lykke-Andersen J, Fritzler MJ, et al. Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J Cell Biol. 2005;169: 871–884. doi: 10.1083/jcb.200502088 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Ariumi Y. Host Cellular RNA Helicases Regulate SARS-CoV-2 Infection. J Virol. 2022. 96:e0000222. doi: 10.1128/jvi.00002-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Bai Z, Cao Y, Liu W, Li J. The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. Viruses. Multidisciplinary Digital Publishing Institute; 2021;13: 1115. doi: 10.3390/v13061115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Peng T-Y, Lee K-R, Tarn W-Y. Phosphorylation of the arginine/serine dipeptide-rich motif of the severe acute respiratory syndrome coronavirus nucleocapsid protein modulates its multimerization, translation inhibitory activity and cellular localization. FEBS J. John Wiley & Sons, Ltd; 2008;275: 4152–4163. doi: 10.1111/j.1742-4658.2008.06564.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses. Multidisciplinary Digital Publishing Institute; 2014;6: 2991–3018. doi: 10.3390/v6082991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Cong Y, Ulasli M, Schepers H, Mauthe M, V’kovski P, Kriegenburg F, et al. Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle. Dutch RE, editor. J Virol. American Society for Microbiology Journals; 2020;94: 181. doi: 10.1128/JVI.01925-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Lu S, Ye Q, Singh D, Villa E, Cleveland DW, Corbett KD. The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein. PlosPath. 2020;18: 479. doi: 10.1101/2020.07.30.228023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Cascarina SM, Ross ED. A proposed role for the SARS-CoV-2 nucleocapsid protein in the formation and regulation of biomolecular condensates. FASEB j. 2020;34: 9832–9842. doi: 10.1096/fj.202001351 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Chen H, Cui Y, Han X, Hu W, Sun M, Zhang Y, et al. Liquid-liquid phase separation by SARS-CoV-2 nucleocapsid protein and RNA. Cell Res. Nature Publishing Group; 2020;30: 1143–1145. doi: 10.1038/s41422-020-00408-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Savastano A, Ibáñez de Opakua A, Rankovic M, Zweckstetter M. Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates. Nature Communications. Nature Publishing Group; 2020;11: 6041–10. doi: 10.1038/s41467-020-19843-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Iserman C, Roden CA, Boerneke MA, Sealfon RSG, McLaughlin GA, Jungreis I, et al. Genomic RNA Elements Drive Phase Separation of the SARS-CoV-2 Nucleocapsid. Mol Cell. 2020;80: 1078–1091.e6. doi: 10.1016/j.molcel.2020.11.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Carlson CR, Asfaha JB, Ghent CM, Howard CJ, Hartooni N, Safari M, et al. Phosphoregulation of Phase Separation by the SARS-CoV-2 N Protein Suggests a Biophysical Basis for its Dual Functions. Mol Cell. 2020;80: 1092–1103.e4. doi: 10.1016/j.molcel.2020.11.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Cubuk J, Alston JJ, Incicco JJ, Singh S, Stuchell-Brereton MD, Ward MD, et al. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nature Communications. Nature Publishing Group; 2021;12: 1936–17. doi: 10.1038/s41467-021-21953-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Sa Ribero M, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathogens. Public Library of Science; 2020;16: e1008737. doi: 10.1371/journal.ppat.1008737 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Gori Savellini G, Anichini G, Gandolfo C, Cusi MG. SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity. Viruses. Multidisciplinary Digital Publishing Institute; 2021;13: 1439. doi: 10.3390/v13081439 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Oliveira SC, de Magalhães MTQ, Homan EJ. Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets. Front Immunol. Frontiers; 2020;11: 587615. doi: 10.3389/fimmu.2020.587615 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes & Infections. 2020;9: 221–236. doi: 10.1080/22221751.2020.1719902 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Parker MD, Lindsey BB, Leary S, Gaudieri S, Chopra A, Wyles M, et al. Subgenomic RNA identification in SARS-CoV-2 genomic sequencing data. Genome Res. Cold Spring Harbor Lab; 2021;31: 645–658. doi: 10.1101/gr.268110.120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Leary S, Gaudieri S, Parker MD, Chopra A, James I, Pakala S, et al. Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. Pathog Immun. 2021;6: 27–49. doi: 10.20411/pai.v6i2.460 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Saffran HA, Pare JM, Corcoran JA, Weller SK, Smiley JR. Herpes simplex virus eliminates host mitochondrial DNA. EMBO Rep. 2007;8: 188–193. doi: 10.1038/sj.embor.7400878 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Corcoran JA, Saffran HA, Duguay BA, Smiley JR. Herpes simplex virus UL12.5 targets mitochondria through a mitochondrial localization sequence proximal to the N terminus. J Virol. 2009;83: 2601–2610. doi: 10.1128/JVI.02087-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020;11: eabe9403–38. doi: 10.1126/science.abe9403 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Nabeel-Shah S, Lee H, Ahmed N, Burke GL, Farhangmehr S, Ashraf K, et al. SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress granules to impair host stress response. iScience. 2022;25: 103562. doi: 10.1016/j.isci.2021.103562 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Luo L, Li Z, Zhao T, Ju X, Ma P, Jin B, et al. SARS-CoV-2 nucleocapsid protein phase separates with G3BPs to disassemble stress granules and facilitate viral production. Sci Bull (Beijing). 2021;66: 1194–1204. doi: 10.1016/j.scib.2021.01.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Zheng Z-Q, Wang S-Y, Xu Z-S, Fu Y-Z, Wang Y-Y. SARS-CoV-2 nucleocapsid protein impairs stress granule formation to promote viral replication. Cell Discov. Nature Publishing Group; 2021;7: 38–11. doi: 10.1038/s41421-021-00275-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Wang J, Shi C, Xu Q, Yin H. SARS-CoV-2 nucleocapsid protein undergoes liquid-liquid phase separation into stress granules through its N-terminal intrinsically disordered region. Cell Discov. Nature Publishing Group; 2021;7: 5–5. doi: 10.1038/s41421-020-00240-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Dougherty JD, Reineke LC, Lloyd RE. mRNA decapping enzyme 1a (Dcp1a)-induced translational arrest through protein kinase R (PKR) activation requires the N-terminal enabled vasodilator-stimulated protein homology 1 (EVH1) domain. J Biol Chem. 2014;289: 3936–3949. doi: 10.1074/jbc.M113.518191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Schmidt N, Lareau CA, Keshishian H, Ganskih S, Schneider C, Hennig T, et al. The SARS-CoV-2 RNA-protein interactome in infected human cells. Nat Microbiol. Nature Publishing Group; 2021;6: 339–353. doi: 10.1038/s41564-020-00846-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Tibble RW, Depaix A, Kowalska J, Jemielity J, Gross JD. Biomolecular condensates amplify mRNA decapping by coupling protein interactions with conformational changes in Dcp1/Dcp2. 2020;60th Anniversary: 600–36. doi: 10.1101/2020.07.09.195057 [DOI] [Google Scholar]
  • 130.Tenekeci U, Poppe M, Beuerlein K, Buro C, Müller H, Weiser H, et al. K63-Ubiquitylation and TRAF6 Pathways Regulate Mammalian P-Body Formation and mRNA Decapping. Mol Cell. 2016;62: 943–957. doi: 10.1016/j.molcel.2016.05.017 [DOI] [PubMed] [Google Scholar]
  • 131.Li Y, Chen R, Zhou Q, Xu Z, Li C, Wang S, et al. LSm14A is a processing body-associated sensor of viral nucleic acids that initiates cellular antiviral response in the early phase of viral infection. Proc Natl Acad Sci USA. 2012;109: 11770–11775. doi: 10.1073/pnas.1203405109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132.Rzeczkowski K, Beuerlein K, Müller H, Dittrich-Breiholz O, Schneider H, Kettner-Buhrow D, et al. c-Jun N-terminal kinase phosphorylates DCP1a to control formation of P bodies. J Cell Biol. 2011;194: 581–596. doi: 10.1083/jcb.201006089 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Stoecklin G, Mayo T, Anderson P. ARE-mRNA degradation requires the 5“-3” decay pathway. EMBO Rep. 2006;7: 72–77. doi: 10.1038/sj.embor.7400572 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Mendoza EJ, Manguiat K, Wood H, Drebot M. Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2. Curr Protoc Microbiol. John Wiley & Sons, Ltd; 2020;57: cpmc105. doi: 10.1002/cpmc.105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Kamentsky L, Jones TR, Fraser A, Bray M-A, Logan DJ, Madden KL, et al. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics. 2011;27: 1179–1180. doi: 10.1093/bioinformatics/btr095 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136.Johnston BP, Pringle ES, McCormick C. KSHV activates unfolded protein response sensors but suppresses downstream transcriptional responses to support lytic replication. Swaminathan S, editor. PLoS Pathogens. 2019;15: e1008185. doi: 10.1371/journal.ppat.1008185 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Ron A M Fouchier, Marjolein Kikkert

14 Dec 2021

Dear Dr. corcoran,

Thank you very much for submitting your manuscript "Human coronaviruses disassemble processing bodies" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

Dear Authors,

Your manuscript was reviewed by three experts in the field. All three reviewers raise concerns about the set-up, description, interpretation and statistics of some of your experiments. Please have a close look at all of these comments and accordingly adapt the manuscript.

Reviewer 1 accidently had entered his/her minor comments in the " editor-only" box, but after inquiry, he/she has confirmed this was a mistake, and these comments should become available to the authors. I cannot change this in the original review report by reviewer 1, but I will paste the text below for the author's convenience:

(minor comments from reviewer 1:)

1 Figure 1D: authors should add the figure of cells infected with SARS-CoV-2 of 16h post-infection.

2 Figure 1F: authors should show more time of Calu3 cells infected with SARS-CoV-2.

3 Figure 2C and 2E: Most of cells (mock) show no PBs, thus, how can authors prove that OC-43 and 229E truly inhibit PBs.

4 Figure 4: Why do authors only examine the level of mRNA. It is required to detect the level of proteins too.

5 Figure 5D: The expression of nsp4, orf9c, orf10 is not examined.

6 Figure 5: The Immunofluorescent results of other proteins of coronaviruses should be supplied.

7 Figure 6: result show that N protein cannot inhibit PBs induced by Ars. What is the difference between PBs of the normal situation and PBs induced by Ars?

8 Figure 7A and B: Why don't you use SARS's N protein? SARS's N should have a similar phenomenon.(less...)

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Marjolein Kikkert

Guest Editor

PLOS Pathogens

Ron Fouchier

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Dear Authors,

Your manuscript was reviewed by three experts in the field. All three reviewers raise concerns about the set-up, description, interpretation and statistics of some of your experiments. Please have a close look at all of these comments and accordingly adapt the manuscript.

Reviewer 1 accidently had entered his/her minor comments in the " editor-only" box, but after inquiry, he/she has confirmed this was a mistake, and these comments should become available to the authors. I cannot change this in the original review report by reviewer 1, but I will paste the text below for the author's convenience:

(minor comments from reviewer 1:)

1 Figure 1D: authors should add the figure of cells infected with SARS-CoV-2 of 16h post-infection.

2 Figure 1F: authors should show more time of Calu3 cells infected with SARS-CoV-2.

3 Figure 2C and 2E: Most of cells (mock) show no PBs, thus, how can authors prove that OC-43 and 229E truly inhibit PBs.

4 Figure 4: Why do authors only examine the level of mRNA. It is required to detect the level of proteins too.

5 Figure 5D: The expression of nsp4, orf9c, orf10 is not examined.

6 Figure 5: The Immunofluorescent results of other proteins of coronaviruses should be supplied.

7 Figure 6: result show that N protein cannot inhibit PBs induced by Ars. What is the difference between PBs of the normal situation and PBs induced by Ars?

8 Figure 7A and B: Why don't you use SARS's N protein? SARS's N should have a similar phenomenon.(less...)

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: PBs are membraneless ribonucleoprotein (RNP) granules found in the cytoplasm of all cells, that mediate decay or translational suppression of cellular mRNAs. PBs or their components are believed to play antiviral roles, however, the impact of which on SARS-CoV-2 infection remains unknow. The authors demonstrate that SARS-CoV-2, OC43 and 229E, induce PB loss. By confocal microscopy and RT-qPCR, authors also found that N protein of SARS-CoV-2 was sufficient to mediate PB disassembly and elevates PBs-regulated cytokine synthesis, thereby reshaping the subsequent immune response. Although these are novel findings and define the impact of SARS-CoV-2 on PBs, but do not truly look at the mechanism by which N inhibits PBs generation. In addition, the direct relation of virus induces PB loss and the elevated transcript levels of selected proinflammatory cytokines needs to be further proved.

Reviewer #2: The manuscript “Human coronaviruses disassemble processing bodies” describes how infection with coronaviruses results in the reduced presence of cytoplasmic puncta that contain known processing body (PB) components in cultured cells. Expression of the N protein from SARS-CoV-2 and not other coronaviruses similarly reduces the presence of PBs in cultured cells. Infection and N expression additionally resulted in the detection of increased transcript levels from a selection of proinflammatory cytokines. The observation that coronaviruses reduce the number of PBs in infected cells is important and the hypothesis that PB disassembly by coronaviruses subsequently increases proinflammatory cytokine transcript levels is very plausible.

I do feel this hypothesis could have been strengthened with the addition of positive controls and have questions regarding inconsistencies in the experimental design and incomplete description of the results and statistical analyses.

Reviewer #3: Robinson et al., have investigated the effects of infection with three human coronaviruses (SARS-CoV-2, OC43 and 229E) on processing bodies (PBs). Previous reports on non-human Coronaviruses (Murine hepatitis virus and transmissible gastroenteritis coronavirus) and PBs have shown virus-specific PB responses. The study by Robinson and colleagues represents an interesting and timely set of descriptive experiments that explore and observe PBs in cells infected with human CoVs. In addition to exploring PB assembly/disassembly in CoV-infected cells some progress has been made to examine viral proteins responsible for PB disassembly and PB-regulated host mRNAs.

While I believe large portions of the work are technically sound, well-executed, and of broad interest, I have major concerns regarding the interpretations of some of the observations and how these observations inform the narrative of PB disassembly. These concerns surrounding the results in figures 4 and 8 reduced my enthusiasm.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: 1. The direct relation of virus induces PB loss and the elevated transcript levels of selected proinflammatory cytokines is poor. The authors should examine the levels of other mRNAs, such as growth factors and angiogenic factors.

2. The mRNA in the PBs can be displayed in FISH assay, which is a direct evidence authors can prove that the mRNA of inflammation factors is imprisoned in PBs (if it is indeed inside).

3. The cellular factor level of five types of ARE-containing was detected. Why did only three expression levels increase? If the author believes that the increase is because of the depolymerization of PBs, even if it does not detect other types of Are-containing RNA included in the PBs, at least these five should be expressed in similar level (figure 4)

4. Inhibition of PBs might indeed release some mRNA, but I tend to think that these mRNAs are regulatory factors that promote transcription of those cytokines.

5. If PBs play antiviral effect with the infection of the SARS-CoV-2, then will inhibition of the formation of PBs promote viral infection? Authors should clarify this point.

6. The results of immunofluorescence should not only show the picture of merge but also show the separate figure.

Reviewer #2: Major

1. Positive controls. Throughout the introduction you indicate that PB disassembly occurs often during viral infection and in Lines 75-76 you state that: “the presence of PBs correlates with presence/suppression of ARE-mRNAs [7,12-15]”. The addition of a positive control known to disassemble PBs (treatment of viral product) would strengthen the hypothesis that the two observations (loss of PBs and increased levels of cytokine transcripts) are linked. Especially because not all ARE-mRNAs tested display similarly elevated levels upon PB disassembly by coronaviruses or SARS-CoV-2 N specifically. If PB disassembly is the sole reason for the enhanced presence of IL-6, COX-2 and or TNF, should we not expect the same pattern when PBs are disassembled by other treatments?

2. Experimental design is not clearly described. All figures: what is n? are these three independent experiments, three wells, of three ‘field of views’? When fold change is presented (1CE, 2DF, 4, 5BC, 6BDF, 7BD, 8, S1A and S2B) it is not always clear what is depicted. Cells expressing PBs? Or PBs per cell? Figure 5BC describes puncta/cell, so how many cells were analyzed from how many wells in how many independent experiments?

3. Most figures are expressed as fold change (1CE, 2DF, 4, 5BC, 6BDF, 7BD, 8, S1A and S2B). In none of these figures the mock or empty vector that samples are normalized to contains error bars. This suggests that for each data point all samples were normalized to the mock, before the average of n=3 was calculated. If this is the case this removes all variance in the mock group and increases the probability that comparison with a sample population results in significant differences. If the authors insist on presenting fold change, the variance in the mock treatment should be maintained, SDs for mock and EV should be presented and statistics should be performed on the raw data.

4. Immunofluorescent images are used to quantify PBs with a previously established pipeline. The materials and methods describes clearly that quantification with the cellprofiler pipeline was done using consistent thresholds and identical parameters (Lines: 543-544). In some images DDX6 or Hedls containing granules are clearly visible but they do not make the cutoff and are displayed as examples of PB negative cells (e.g. virus infected Zoom images of Figures 1 and 2). To make a fair comparison, not only subsequent quantification analysis but also initial exposure times have to be identical between PB positive and negative (mock and infected) samples. Please provide key information on the exposure times and additionally list the make and model of the microscope.

5. Unclear why in figure 4 COX-2 is examined and found to change significantly upon SARS-CoV-2 infection, while after figure 4 the COX-2 transcript is not mentioned again and for figure 8 TNF is measured. Line 290 even states TNF was elevated after virus infection (Fig.4), while I cannot find TNF anywhere in figure 4. Without clear arguments for this inconsistency, using COX-2 in Fig.4 and TNF in Fig. 8 feels like cherry picking. Furthermore, please clarify why only for Fig. 8 and not Fig. 4 cells were stimulated with TNF.

Reviewer #3: My major concern with the study is the analysis of PB-regulated cytokine mRNAs presented in Figures 4 and 8. The genes tested include IL-6, CXCL8, COX-2, GM-CSF, and IL-1B. These genes are commonly associated with many inflammatory or IFN cascades. Their upregulation and PB-regulation are not definitively linked, and it is more likely that their upregulation is a consequence of IFN/immune signalling than of PB disassociation.

Additionally, in the functional characterisation of these genes in N overexpression (Fig 8), there is no convincing link between the PB disassembly and expression of these genes. Indeed, the expression of these genes is not significantly associated with SARS-CoV-2 N protein overexpression as only one cytokine (TNF) was significantly increased. The title of Figure legend 8 "Ectopic expression of SARS-CoV-2 N elevates selected ARE-mRNAs" is therefore misleading as there is only one upregulated mRNA that is statistically significant. Additionally, the data showing the no effect of TNF treatment on PB numbers should be presented.

It is surprising that authors did not use their Luciferase-ARE reporter assay (included in the pre-print version) to directly link the effect of SARS-CoV-2 infection and protein expression on PB-associated turnover of ARE-containing mRNA transcripts.

For Figure 6: While it looks like there is a difference in PB numbers/fold change between control (EV) and N in Figures 6 D and F, unfortunately, there are no statistics performed. I suppose this may be due to only two replicates of this experiment. At least 3 experiments are required to clarify this. Additionally, it is peculiar that there appears to be slightly more PB assembly in the sodium arsenate treatment when comparing the empty vector and N protein assembly. The reasons for the lack of effect on N on PB disassembly following sodium arsenate treatment need to be at least discussed.

Fig 7. There seem to be lower expression for OC43 and NL63 N proteins than for SARS-CoV-2 which could partially explain lesser effect on PB disassembly. Could authors comment on this? Some form of quantitative analysis of protein expression in western blots in this and other figures (e.g. densitometry of bands) should be presented to justify the conclusions.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: (No Response)

Reviewer #2: Minor

Lines 45-47: Sentence unclear. The relevance only becomes clear after reading the introduction of the manuscript. Moreover, also line 55 describes transcript levels as ‘repressed’. When reading the abstract on its own I am left wondering where? How? and why? Again this all becomes perfectly clear in the introduction of the main text.

Lines 57-60 and lines 108-111: The conclusion that proinflammatory cytokine mRNA levels are increased as an unintended side-effect of SARS-CoV-2 infection is a bit of an odd and counterintuitive note. Firstly, by calling it an unintended side effect it suggests there is no benefit for the virus, leaving no room for tradeoffs with potential positive effects on virus transmission in a natural situation. Secondly, refrain from using the word ‘unintended’ as viruses do not act with intent.

Line 164: Could use a rationale why Fig. 1F is performed at 48 and not 24hpi

Lines 193-194: Fig. 3C, was infection with 229E confirmed?

Figure 5B-D: Viral protein products are labelled differently (E vs env, S vs spike etc)

Figures: abbreviation EV (empty vector) should be explained well before the legend of Figure 8.

Line 548: Check with a statistician whether paired Student’s t-tests are correct. It is my understanding that when comparing cells that have undergone different treatments the test should be unpaired.

Reviewer #3: It is unclear how many experiments were undertaken and what data represents what biological samples for many of the figures.

The convention in the figure legends appears to be set out by the figure legend one for western blots. “Representative images from one of two independent experiments are shown. n=2.” However, only the “n=x” is shown for figures with bar graphs but not pooled for the analysis or mentioned if the trends are the same. If possible, can the results from all experiments be pooled to show the robustness of the data and treatments?

For figure 1, Hedls puncta are quantitated for figure 1 but not for Figure 2. Is there any reason why this was omitted for the other CoVs or can the authors defend the sole use of one puncta quantitation? This is important given that for figure 3, there is quite a pronounced reduction in DDX6 in whole-cell lysates, and while it would make sense there would be less PB machinery, is there the same reduction in Hedls puncta.

Additionally, while it is clear that the DDX6 puncta are drastically less in the Calu cells in figure 1F these have not been quantitated as have the previous figures. Maybe this could be added for the completeness of the figures.

For figure 3 the title is too strong given that one of these viruses does reduce DDX6. For western blots used for comparison and quantitation, could densitometry analyses be performed and statistically assessed.

In figure 5D I am not sure what C145A corresponds to in the western blot, and it is not clear what it is from the text.

Line 444: Origin of FBS.

Line 467: I believe “polyethylimine” should be polyethylenimine

Section Lines 493: Could it be clarified what the target host transcript(s) is/are being used for normalisation.

Line 505: As there are phenotypic differences between isolates and clades of SARS-CoV-2, could the GISAID accession number associated with this isolate be added to the text here? Also, maybe one comment about the lineage designation (Alpha Beta etc).

Line 532: Could the version of CellProfiler be added to this.

Line 594: G should be F

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 1

Ron A M Fouchier, Marjolein Kikkert

5 Apr 2022

Dear Dr. Corcoran,

Thank you very much for submitting your manuscript "Human coronaviruses disassemble processing bodies" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Your revised manuscript has been reviewed by the three original reviewers. All conclude that the manuscript has improved. However, two of the three reviewers still have concerns, especially about the newly added Fig. 9.

The new figure partly supports the conclusions about cytokine encoding RNAs being present in PBs, however, the conclusion that these are released from PB upon expression of SARS-CoV-2 N protein, as is claimed, is not supported strongly enough by the new data. Reviewer 3 therefore suggests to reconsider the formulation of the conclusions, or add data that does support the claim sufficiently. I agree with reviewer 3 that this is necessary. I also agree with reviewer 2 and 3 that statistical analysis of the new data should be presented more clearly.

Please reply to the reviewers comments to your revised manuscript and adjust the manuscript and figures accordingly.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Marjolein Kikkert

Guest Editor

PLOS Pathogens

Ron Fouchier

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Your revised manuscript has been reviewed by the three original reviewers. All conclude that the manuscript has improved. However, two of the three reviewers still have concerns, especially about the newly added Fig. 9.

The new figure partly supports the conclusions about cytokine encoding RNAs being present in PBs, however, the conclusion that these are released from PB upon expression of SARS-CoV-2 N protein, as is claimed, is not supported strongly enough by the new data. Reviewer 3 therefore suggests to reconsider the formulation of the conclusions, or add data that does support the claim sufficiently. I agree with reviewer 3 that this is necessary. I also agree with reviewer 2 and 3 that statistical analysis of the new data should be presented more clearly.

Please reply to the reviewers comments to your revised manuscript and adjust the manuscript and figures accordingly.

Reviewer Comments (if any, and for reference):

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: (No Response)

Reviewer #2: This manuscript puts forward an interesting hypothesis on how virus mediated PB loss can increase the availability of cytokine mRNA. The revised version of the manuscript contains considerable improvements in (the description of) experiments and analyses. This clarifies many of my initial questions and certainly improves transparency. With the added RNA-FISH experiment the authors also strengthen their observations. My only comment is that the description and interpretation of this new RNA-FISH experiment can be improved.

Reviewer #3: Most of my queries have been addressed except one of the major concerns (see Major issues)

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: Authors provide new data (Fig 9B,C) that they claim are showing release of IL6 and TNF mRNAs from disassembled PBs in cells transfected with N-expressing plasmid along with qRT-PCR data of total cell RNA for these mRNAs. While I can accept that Fig 9A does show some co-localization of IL6 and TNF mRNAs in mock cells treated with TNFa, there is no FISH marker for PBs in Fig 9B (as it was in Fig 9A) to justify their conclusion. Yes, there appears to be more TNF mRNA in N-expressing cells but without PB marker it is not possible to conclude that this is the result of TNF mRNA release from disassembled PBs. RT-qPCR of total cell RNA while does show more TNF mRNA (only two repeats though) it doesn't prove that this mRNA is released from disassembled PBs.

I think authors should either provide definitive experimental proofs that cytokine mRNAs are indeed released from disassembled PBs in N-expressing cells or remove this conclusion from the manuscript.

This also refers to their argument against showing data on ARE-containing luciferase reporter assay as RT-qPCR data in the new Fig 9C show no statistically significant difference in IL6 and TNF mRNAs in N-expressing cells.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: (No Response)

Reviewer #2: New figure 9C. it is unclear to me what the errorbars stand for and why there is no statistics. In the discussion you mention that differences in RNA levels (Fig10) are insignificant, though in your rebuttal and main text of the manuscript you do refer to IL6 and TNF as being upregulated and/or having a higher signal intensity. Without statistics I do think you have to carefully formulate this conclusion, especially regarding IL6 as differences both in figs 9 and 10 are small and have considerable variation between replicates. Perhaps doing statistics and reporting the p-values, even when not significant, can make these results better interpretable to readers.

Reviewer #3: Why there is now no PB disassembly in N-expressing cells vs EV control cells in Fig 7D? This contradicts other findings in this manuscript claiming key role of N protein in PB disassembly.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Decision Letter 2

Ron A M Fouchier, Marjolein Kikkert

3 Jun 2022

Dear Dr. Corcoran,

Thank you very much for submitting your manuscript "Human coronaviruses disassemble processing bodies" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

One reviewer still has some concerns about the newly added figure. Please try and address these by adjusting the text and/or adding quantification as suggested.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Marjolein Kikkert

Guest Editor

PLOS Pathogens

Ron Fouchier

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Dear Dr. Corcoran,

One reviewer still has some concerns about the newly added figure. Please try and address these by adjusting the text and/or adding quantification as suggested.

Reviewer Comments (if any, and for reference):

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #2: The authors have sufficiently addressed my concerns by adding new experiments in what is now fig 9 and clarifying the methods and statistical analyses. I have no further comments.

Reviewer #3: (No Response)

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #2: (No Response)

Reviewer #3: While I appreciate that the authors have addressed our concerns with the follow up experiment (Fig 9D,E), to the untrained eye it does not look like there is much of an increase in signal in the bottom panel TNF RNA transcripts in the new Fig 9E (between the two EV and SARS-CoV-2 N bottom panels). I believe we should be seeing more signal or more diffuse RNA transcript signal? Could this be made clearer either through quantitation here in this figure or in a supplementary figure (there is white space under the image that could be used).

With the addition of this experiment and figure it appears that in SARS-CoV-2 N overexpressing cells there is a considerable increase in the Hedls protein level as compared to the EV (Fig 9D,E)? I understand that Hedls protein level was not changed in the SARS-CoV-2 infection at 6 or 12 hours (Fig 4A). Additionally, It doesn’t look like the PBs (appearance of puncta) are reduced or disassembled. Instead it appears that the surrounding signal is stronger suggesting a higher abundance of Hedls rather than disassembly and cytoplasmic redistribution. Is this what was expected from this experiment? Could the authors clarify this observation?

In addition, I raised the concern about lack of demonstrated PB disassembly in Fig 7D, which the authors explained as an outlier experiment. However, new Fig 9D and E also in my opinion don't show PB disassembly (see comment above). Are these data also come from an outlier experiment? This needs to made clear in the text.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #2: (No Response)

Reviewer #3: A minor issue to address is Dapi should be written DAPI in this figure and others and in multiple places in text.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Decision Letter 3

Ron A M Fouchier, Marjolein Kikkert

4 Jul 2022

Dear Dr. Corcoran,

We are pleased to inform you that your manuscript 'Human coronaviruses disassemble processing bodies' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Marjolein Kikkert

Guest Editor

PLOS Pathogens

Ron Fouchier

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

The authors have adjusted the text after the second revision to more accurately formulate the conclusions.

Reviewer Comments (if any, and for reference):

Acceptance letter

Ron A M Fouchier, Marjolein Kikkert

16 Aug 2022

Dear Dr. Corcoran,

We are delighted to inform you that your manuscript, "Human coronaviruses disassemble processing bodies," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. HUVEC-ACE2 cells are permissive to SARS-CoV-2.

    A. HUVECs were transduced with recombinant lentiviruses expressing human ACE2 (HUVECACE2), selected, and infected with SARS-CoV-2 (TO-1 isolate; MOI = 3). 6 and 24 hours post-infection, virus-containing supernatant was harvested and titrated by TCID50 assay in VeroE6 cells. These data represent two independent experiments (n = 2); mean ± SD. B-C. HUVECs were transduced with ACE2 as in A. Cells were fixed and immunostained for DDX6 (B) or Hedls (C) and quantified per field of view using CellProfiler. These data represent two independent experiments (n = 2) with >100 cells measured per condition. Each EV and ACE2 replicate pair plotted independently; mean. Statistics were performed using a Mann-Whitney rank-sum test (ns, nonsignificant).

    (TIFF)

    S2 Fig. HUVECs are permissive to OC43 and 229E infection.

    A-B. HUVECs were infected with OC43 (TCID50 = 2 x 104) or 229E (TCID50 = 2.4 x 103). 6-, 12-, or 24 hours post infection, virus-containing supernatant was harvested and titrated using TCID50 assay in VeroE6 (A) or MRC5 (B) cells, respectively. These data represent two independent experiments (n = 2); mean ± SD. C. HUVECs were infected with 229E as in B or mock infected. Total RNA was harvested 12 hours post infection and RT-qPCR was performed using primers specific to 229E genomic RNA (gRNA) or subgenomic RNA8 (sgRNA8), or HPRT (cellular house-keeping gene). Cycle-threshold (Ct) values for each primer pair were plotted. These data represent three independent experiments (n = 3); mean ± SD. Ct values greater than 35 were not deemed biologically relevant and therefore are scored as N/A. D. PCR products from C were resolved using agarose gel electrophoresis. gRNA fragment migrated at the expected size of 285 bp. sgRNA fragment migrated at its expected ~80 bp. Representative images from one of two independent experiments are shown.

    (TIFF)

    S3 Fig. Hedls puncta are absent in OC43 and 229E infected cells.

    A. HUVECs were infected with OC43 (TCID50 = 2 x 104) or mock-infected. 12 or 24 hours post infection cells were fixed and immunostained for DDX6 (green; Alexa488) and Hedls (white; Alexa555). Nuclei were stained with Hoechst (blue). Representative images from one of three independent experiments shown. B. Hedls puncta in OC43-infected or mock-infected cells were quantified per field of view using CellProfiler. C. HUVECs were infected with 229E (TCID50 = 2.4 x 103) or mock-infected. 6 or 12 hours post infection cells were fixed and immunostained for DDX6 (green) and Hedls (white). Nuclei were stained with Hoechst (blue). Representative images from one of three independent experiments shown. D. Hedls puncta in 229E-infected or mock-infected cells were quantified as in B. These data represent three independent experiments (n = 3) with ≥100 cells measured per condition per replicate. Each mock and infected replicate pair plotted independently; mean. Statistics were performed using a Mann-Whitney rank-sum test (****, p < 0.0001). Scale bar = 20 μm.

    (TIFF)

    S4 Fig. Processing body protein densitometry after human coronavirus infection.

    A. HUVECs were transduced with human ACE2 (HUVECACE2), selected, and infected with SARS-CoV-2 TO-1 isolate (MOI = 3). Cells were lysed at 6 and 12 hours post infection and immunoblotting was performed using XRN1, Hedls, DCP1A, DDX6, SARS-CoV-2 N, and β-actin specific antibodies. The results of the second independent experiment of two is shown. B-C. HUVECs were infected with OC43 (TCID50 = 2 x 104) or 229E (TCID50 = 2.4 x 103) or mock-infected. Cells were lysed at 12 and 24 hours post infection (B, OC43) or 6 and 12 hours post infection (C, 229E). Immunoblotting was performed using DDX6, Hedls, XRN1, DCP1A, and beta actin specific antibodies. Protein densitometry was determined in ImageJ normalized to beta actin and expressed as a fold-change relative to the 12 hours post infection (B; OC43) or 6 hours post infection (C; 229E) mock-infected control. These data represent three independent biological replicates (n = 3). A one-way ANOVA with a Dunnett’s post-hoc analysis was performed; mean; bars represent SD (*, p < 0.05).

    (TIFF)

    S5 Fig. Ectopic expression of SARS-CoV-2 ORFs.

    HeLa cells expressing GFP-Dcp1a were transfected with an empty vector (EV) control or 2X Strep-tagged SARS-CoV-2 ORFs for 48 hours then fixed and immunostained for Strep-tag II (viral ORF; green; Alexa647) or DDX6 (PBs; white; Alexa555). Nuclei were stained with Hoechst (blue). A. SARS-CoV-2 ORFs that could be detected by Strep-tag II staining (thresholded ORFs). B. SARS-CoV-2 ORFs that could not be detected by Strep-tag II staining (unthresholded ORFs). Representative images from one of three or more independent experiments shown. Scale is the same for all images. M = membrane protein, S = spike protein.

    (TIFF)

    S6 Fig. Validation of processing body loss induced by selected SARS-CoV-2 ORFs in HUVECs.

    A. HUVECs were transduced with recombinant lentiviruses expressing 2X Strep-tagged SARS-CoV-2 nsp1, nsp14, ORF3b, and ORF7b constructs or control lentiviruses (EV) and selected with puromycin for 48 hours. Cells were fixed and immunostained for Strep-tag II (ORFs; green; Alexa488) and DDX6 (PBs; white; Alexa555). Nuclei were stained with Hoechst (blue). Representative images from one of three independent experiments shown. Scale bar = 20 μm. B. DDX6 puncta were quantified per field of view using CellProfiler. These data represent three independent experiments (n = 3) with >18 cells measured per condition per replicate. Each EV and ORF-expressing replicate pair plotted independently; mean. Statistics were performed using Kruskal-Wallis H test with Dunn’s correction (**, p < 0.0021; ****, p < 0.0001; ns, nonsignificant). C. HUVECs were transduced as in A. Cells were lysed and immunoblotting was performed using the Strep-Tag II antibody on a 4–15% gradient gel.

    (TIFF)

    S7 Fig. Processing body protein densitometry after CoV N protein overexpression.

    A-C. HUVECs were transduced with recombinant lentiviruses ectopically expressing N protein from the Betacoronaviruses MERS-CoV and OC43 (A), N protein from Alphacoronaviruses 229E and NL63 (B) or SARS-CoV-1 N (C). A control lentiviral expressing an empty vector (EV) was used as a negative control and SARS-CoV-2 N protein expressing lentiviruses were used as a positive control in each experiment. Cells were selected and lysed and immunoblotting was performed using XRN1, Hedls, DCP1A, DDX6, N protein or FLAG, and beta actin specific antibodies. Protein densitometry was determined in ImageJ normalized to beta actin and expressed as a fold-change relative to the EV control. These data represent three independent biological replicates (n = 3). A one-way ANOVA with a Dunnett’s post-hoc analysis was performed; mean; bars represent SD (*, p < 0.05).

    (TIFF)

    S8 Fig. TNF treatment does not alter processing body number.

    HUVECs were treated with 0.01 ng/L soluble TNF for either 6 or 12 hours following which, cells were fixed and immunostained for Hedls. Nuclei were stained with Hoechst. Hedls puncta were quantified per field of view using CellProfiler. These data represent two independent experiments (n = 2) with >90 cells measured per condition per replicate. Each mock and infected replicate pair plotted independently; mean.

    (TIFF)

    S9 Fig. Processing body loss correlates with elevated TNF RNA after ectopic expression of SARS-CoV-2 N protein.

    A-B. Cells were treated and immunostained as in Fig 9B and Hedls puncta (white; Alexa488) were quantified per field of view using CellProfiler. Scale bar = 20 μm. These data represent three independent experiments (n = 3) with >75 cells measured per condition per replicate; mean. Statistics were performed using a Mann-Whitney rank-sum test (****, p < 0.0001). C-D. HUVECs were transduced with recombinant lentiviruses ectopically expressing SARS-CoV-2 N or an EV control. Cells were selected, fixed and immunostained for either Hedls (green; Alexa488) and SARS-CoV-2 N (red; Alexa555) prior to hybridization with Stellaris probes specific for GAPDH and TNF (grey; Quasar 670). Nuclei were stained with DAPI. Cells were imaged using a Zeiss LSM 880 laser scanning confocal microscope and the 63X objective. Representative images from two independent experiments are shown. Each channel is shown separately in black and white, including an inverted image of the RNA FISH channel, prior to merged images. Scale bar = 5 μm.

    (TIFF)

    Attachment

    Submitted filename: Corcoran Kleer Mulloy Response to Reviewers.pdf

    Attachment

    Submitted filename: Corcoran Kleer Mulloy Response to reviewers FINAL.pdf

    Attachment

    Submitted filename: Kleer Mulloy Response to Reviewers.pdf

    Data Availability Statement

    All relevant data are within the manuscript and its supporting files.


    Articles from PLoS Pathogens are provided here courtesy of PLOS

    RESOURCES